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CHAPTER I 
 
INTRODUCTION 
 
Specific Aims 
The primary goal of the National Bone and Joint decade is to foster the discovery 
and development of novel therapeutics and treatments for skeletal disorders.  Spine-
related applications would benefit greatly from the development of injectable and in situ 
curable biomaterials. Spinal fusion is a procedure that eliminates or minimizes motion at 
a site of degeneration in the spinal column.  When fusion procedures yield new bone 
that welds the transverse processes or the vertebral bodies, the stability of the spinal 
column is enhanced without dramatically altering spine motion as a whole.  The 
osteoinductive material of choice for grafting is autograft harvested from the iliac crest.  
The use of autograft is dictated by limited availability at the donor site (1) and post-
operative morbidity due to long-term discomfort at the donor site (2).  Furthermore, in 
cases of revision procedures and/or when previous iliac crest harvest has been made, 
the autograft option is an untenable one.  These limitations form the basis and serve as 
the motivating elements in the development of synthetic alternatives.   An ideal 
polymeric biomaterial for these applications provides immediate mechanical stability, 
degrades over time in order to promote new bone growth, and promotes no adverse 
immune response.  To fulfill these three criteria, the following characteristics are desired 
for bone regenerative biomaterials: capability of in situ formation, conformability to the 
implantation site, controlled degradation and retention of mechanical characteristics.  
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Additionally, the material should be readily modifiable to include osteogenic factors or 
components which minimize local pH alterations, as local acidity can induce 
inflammation and impair bone healing (3).  This combination of features is ideal for 
complex fractures, bony defects, or spinal augmentations which require immediate 
mechanical support yet would benefit from material degradation and eventual 
replacement by bone.   
 The focus of this work therefore, was to develop an injectable, in situ curable, 
biodegradable biomaterial for spinal fusion.  In this study, photocurable methacrylated-
anhydride monomers were formulated into injectable pastes.  Reactive diluents 
(polyethylene glycol diacrylate (PEGDA) and nonreactive fillers (calcium carbonate 
(CaCO3)) will be incorporated. The choice of the anhydride system was based on its 
similarity to PMMA with respect to crosslinking chemistry, while simultaneously affording 
degradability to biomaterial.  In this dissertation, a thorough evaluation of the in vitro 
degradation and biocompatibility of the photocrosslinked poly(anhydride) networks is 
provided.  In addition, the capabilities of the materials to deliver bioactive molecules are 
assessed in in vitro studies.  The following specific aims were pursued.  
 
Aim 1 – Characterize in vitro degradation parameters for bone graft substitutes 
composed of surface-eroding poly-anhydrides 
 
In this aim, we have evaluated the in vitro degradation characteristics of 
photocrosslinked networks composed of sebacic acid dimethacrylate (MSA), 1,6-bis-
carboxyphenoxyhexane dimethacrylate (MCPH), and PEGDA in varying proportions, 
with or without the presence of additives such as calcium carbonate.  We have 
evaluated the swelling, mass loss, and mechanical properties at varying time points.  In 
 2
addition, the effect of degradation on local pH was evaluated as a function of time.  This 
aim resulted in optimization of network formulation for further use in Aims 2 and 3. 
 
Aim 2 – Evaluate in vitro release of proteins from surface eroding polyanhydrides 
In this aim, we have evaluated the in vitro release of model proteins from three-
dimensional photocrosslinked networks composed of MSA, MCPH and PEGDA.  
Formulations demonstrating favorable degradation parameters (including pH profile, 
mass loss, swelling, and mechanical strength as well as reproducibility in fabrication 
and ease of handling) in Aim 1 were assessed for their capabilities of sustained release 
of proteins. For incorporation into the photocrosslinked poly(anhydride) networks, 
proteins were titurated with a hydroxypropyl-β-cyclodextrin excipient to minimize the 
potential for free radical or photothermal damage, to stabilize the protein, and to enable 
accurate measurement of low levels of proteins.  We employed a gelatin-based wet 
granulation technique on the protein:excipient mixture to further protect proteins from 
free radical or photothermal damage that may occur during crosslinking.  By using an 
excess of excipient (1:100 protein:excipient) and gelatin granulation, a barrier was 
formed that minimizes the probability of damage occurring to the protein.  Release 
profiles of active enzymes were assessed using horseradish peroxidase, bovine serum 
albumin conjugated with fluoroscein isothiocyanate, and insulin as model proteins.  
Metrics included establishing protein integrity after crosslinking and achieving release 
for a minimum of 4 weeks in vitro. 
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Aim 3 – Modulate in vitro release of proteins from surface eroding polyanhydrides via 
incorporation of additives 
 
 In Aim 2, the release of several model proteins has been achieved from 
photocrosslinked polyanhydride networks.  However, in initial polymer formulations, the 
rate of protein release is slower than desired.  In Aim 3, the methodology developed in 
Aim 2 was used and expanded upon to modulate rates of protein release. A particulate 
leaching strategy was employed to induce network microporosity and facilitate protein 
release.  Sodium chloride crystals and gelatin microparticles were explored for their 
capabilities of modulating protein release.  Additionally, protein-loaded gelatin 
microparticles were incorporated into photocrosslinked matrices as a composite vehicle 
for sustained release. 
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Overview and Rationale  
The decade spanning 2002 – 2011 has been designated the National Bone and 
Joint decade, in part to highlight the negative impact of skeletal degenerative diseases 
on productivity and quality of life and in addition to foster discovery and development of 
new treatment options.  Among disorders and diseases associated with the 
musculoskeletal system, low back pain has assumed epidemic proportions, accounts for 
more physician visits than any diagnosis other than the common cold and is estimated 
to affect over 90% of Americans, with a financial impact in the billions of dollars due to 
lost man-hours and related medical costs (4).  In an ageing population, the primary 
cause of lower back pain is degenerative changes that arise due to overgrown joints in 
the lumbar region of the spine subsequent to arthritis.  These degenerative changes 
over time can cause a progressive narrowing of the spinal canal resulting in 
compression of the spinal nerve roots resulting in pain, local inflammation and onset of 
vertebral body segments instability (4).  This condition is called Lumbar Spine Stenosis 
(LSS), which disproportionately affects the middle-aged and elderly population, has 
been implicated as the primary cause of lower back pain (4).  Further progressive 
degeneration can result in slippage of the vertebral processes, leading to a condition 
called degenerative spondylolisthesis.  Currently, non-surgical options include 
controlling inflammation and pain through systemic and localized administration of 
medications and physical therapy.  Surgery involves relieving the spinal nerve root 
compression via decompressive laminectomy along with spinal fusion.  Spinal fusion is 
procedure used to treat conditions that result in weakening of the spinal column due to 
localized trauma and disorders ranging from (1) injuries to spinal vertebrae, (2) 
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degeneration of disk (herniated or slipped disk) leading to degenerative 
spondylolisthesis (3) abnormal curvatures (scoliosis and kyphosis) and (4) weak or 
unstable spine caused by infections or tumors (AAOS).  The primary goal of spinal 
fusion, therefore, is to eliminate motion at the site of degeneration of the spinal column 
thereby improving overall spinal column stability. This is accomplished by “welding” the 
vertebral processes in question using a grafting material that is replaced by a solid 
volume of bone over time.  This stabilization includes posterolateral intertransverse 
fusion to restore alignment and stability to the spine and/or interbody fusion.  Since the 
fusion procedures typically involve no more 2-3 sequential spinal segments, overall 
motion to the spine is not compromised.  A spinal fusion procedure is typically 
accompanied by augmentation of the spinal column with internal devices such as metal 
rods.  Annually, over 400,000 spinal fusion procedures are performed in the United 
States, with over 50% of those involving the lower spine, namely lumbar fusion.  
Alarmingly, the rate of lumbar fusion surgery for the treatment of LSS saw a relative 
increase of 220% from 1990 to 2001 to over 122,000 lumbar fusion procedures in 2001 
alone (5).   
Current hurdles that clinicians face in restoring spine stability include achieving 
predictable bone fusion particularly in cases of revision spine surgery, elderly patients 
and smokers.  The grafting material of choice, i.e., the ‘gold standard’ is autogenous 
bone from the iliac crest.  In a human, typically no more than 15 cc of bone can be 
harvested from the iliac crest (1).  This additional procedure results in significant pain 
and morbidity and furthermore, is non-tenable option in patients who have already 
undergone harvest for other surgical procedures (2).  This has prompted the exploration 
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of other alternatives and they include pre-fabricated grafts, injectable tri-calcium 
phosphate pastes and collagen-BMP systems.  Pre-fabricated grafts neither provide 
stability nor promote new-bone formation easily.  Tri-calcium phosphate (TCP) pastes 
are utilized as non-weight bearing bone void fillers, and require supplementation with 
hydroxyapatite (HA) or growth factors such as rhBMP-2 or TGF-β to facilitate new bone 
growth (6).  Collagen-BMP systems while capable of inducing new-bone formation do 
not provide immediate stabilization to the spinal column at the site of application.  
Therefore, the current need in spinal fusion surgery is a material that (a) provides 
immediate structural stability for spinal stabilization, (b) allows for easy conformability to 
defect site but degrades over time producing a fusion rate comparable to or better than 
autografts and current materials and (c) is replaced by bone.  The focus of this proposal 
therefore, is to develop an in situ curable biomaterial for spinal procedures.  In the 
proposed study, photo-curable methacrylated-anhydride monomers will be formulated 
into injectable pastes and augmented with osteogenic factors.  The choice of the 
anhydride system is based on its similarity to polymethyl(methacrylate) (PMMA) with 
respect to crosslinking chemistry, while affording degradability to biomaterial.  While, 
degradable alternatives to autograft have been explored, these efforts have primarily 
focused on the development of calcium phosphate bone cements (7-10) with the 
exception of poly(propylene-co-fumarate) (PPF) which is discussed later in this section.  
The focus of this proposal therefore, is to develop an injectable, in situ curable 
biomaterial for minimally invasive spinal procedures.  The choice of the anhydride 
system is based on its similarity to PMMA with respect to chemistry, while affording 
degradability to biomaterial. In this study, photo-curable methacrylated-anhydride 
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monomers were formulated into injectable pastes.  The paste was photocrosslinked and 
its in vitro degradation properties were evaluated.  In addition, its capabilities for release 
of active biomolecules were assessed.  
 
Degradable biomaterials in orthopedics 
The poly(α-hydroxy acids) (PHAs)  such as poly(lactic acid), poly(glycolic acid) 
and their copolymers have garnered the most attention amongst biocompatible, 
degradable polymers. Although the PHAs have had long standing success as surgical 
sutures, their use in bone replacement or augmentation has been limited. A primary 
source of this limitation is the lack or reactive moieties that prevent the PHAs from being 
injected and crosslinked in situ. 
It is fairly well established that PHAs primarily undergo degradation via bulk 
erosion (11). A shortcoming of this degradation pattern is the accumulation of acidic 
degradation products due to end-stage hydrolysis (12). When the mass of the degrading 
polymer matrix is significantly large, the local concentration of soluble degradation 
products (monomers and oligomers) can reach levels adequate to lower the local pH 
(13). It is believed that local acidity can induce inflammation and thus impair bone 
healing (3). In addition, pockets of accumulated degradation products can occur, 
resulting in a net porosity increase throughout the degradative lifetime of the polymer.  
This is particularly detrimental in bone replacement situations, as the net increase in 
porosity causes a net decrease in mechanical strength. Thus the effective lifetime of the 
device could be much less than the theoretical lifetime based on mass calculations.  In 
contrast to the PHAs, poly(anhydrides) (14, 15) (PA) undergo degradation 
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predominantly via surface erosion (16).  The advantages of the surface eroding system 
in bone augmentation applications are twofold. Surface erosion is dictated by the 
presence of highly insoluble degradation products.  Although the degradation products 
of the PAs are also acids, the monomers are intentionally designed to have low 
solubility and hence the degradation products are less likely to contribute to local acidity 
under physiological conditions. As a result, devices fabricated from these polymers are 
less likely to alter the local pH during their degradative lifetime. A second advantage 
conferred by the surface eroding characteristics of the PA system is the maintenance of 
mechanical strength during the course of degradation.  Tensile modulus changes of less 
than 20% have been seen at up to 50% mass loss in photocrosslinked polyanhydride 
systems (17, 18).  
Another consideration in the development of materials for use in spinal 
applications is control over degradation behavior. The ability to vary degradation 
behavior in a predictable manner is of extreme significance in ensuring new bone 
formation. It is desirable that the degradation/erosion rates match new bone ingrowth. In 
the PA system the degradative lifetime of the polymer can be varied from a few days to 
few years by changing the relative hydrophobicity of the monomers and the co-
monomer composition in the polymer (19). Such flexibility in degradation properties is 
however absent in the PHAs without significant chemical modification. 
Although, poly(esters) derived from propylene glycol and fumaric acid 
(unsaturated diacid) are being evaluated for bone cement applications with moderate 
success (20-22), they lack the versatility in chemical structure to allow for tailoring of 
erosion behavior and curing kinetics. In fact the poly(propylene-co-fumaric acid) system 
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(PPF), by virtue of it being an alternating polymer, has a fixed concentration of 
unsaturated linkages per polymer chain. This typically results in a very high cross-link 
density yielding brittle structures, a problem which is only offset by adding excipients 
and filler agents to decrease the cross linking. Furthermore, aliphatic vinyl groups have 
very poor reactivity, requiring the use of highly reactive and toxic reactive diluents such 
as vinyl pyrrolidone to improve the kinetics of cross-linking. Finally, aliphatic 
unsaturation in absence of an adjacent activating group is not amenable to cross-linking 
via light radiation.  
We believe that biodegradable polymers if designed and formulated properly can 
yield a viable osteoconductive conduit for bone repair and replacement in spinal 
procedures. We have developed an anhydride based polymer system bearing reactive 
methacrylate functionalities that cure rapidly upon exposure to UV or visible radiation to 
produce high strength degradable networks that have degradative lifetimes ranging from 
a few days to months (17). This novel system addresses many of the limitations of the 
PPF system and can be developed into an injectable, photo-curable system for bone 
regeneration. 
 
Polyanhydrides as drug delivery vehicles 
Polyanhydrides have been studied for a variety of sustained release applications, 
primarily as a direct result of their surface erosion properties.  The predictable 
degradation profile results in a similarly predictable release profile for drugs, proteins, or 
other molecules. Polyanhydrides are currently approved by the FDA as an implantable 
device for the delivery of BCNU in the treatment of glioblastoma multiforme – a fatal 
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form of brain cancer (23, 24).  Polyanhydride microspheres have been evaluated for the 
release of a variety of molecules, including rhodamine B (25, 26), FITC-BSA (27), 
plasmid DNA (25), p-nitroaniline (26, 28), piroxicam (26), and BSA (28).  In addition, 
photocrosslinked polyanhydride networks have demonstrated a modest capability to 
deliver plasmid DNA (29). 
 Sustained release of osteogenic cytokines and growth factors from polymer 
scaffolds for imparting osteoinductivity has been the focus of much research (30-36).  
Utilization of a potent osteoinductive molecule, such as BMP-2, in a photocrosslinked 
polyanhydride matrix will add an additional benefit to the system for applications in 
spinal repair. 
 
Role of BMPs in bone remodeling 
Bone is a very dynamic and metabolically active tissue that remodels throughout 
ones lifetime. This process is governed by a complex interplay between molecular cues 
in the form of soluble growth factors (GFs) such as bone morphogenetic proteins 
(BMPs), and mechanical cues. The bone healing process is a complex multi-faceted 
pathway which can be expedited by a bone graft. The stages of bone healing are 
inflammation, vascularization, osteoinduction, osteoconduction and remodeling (37).  
Inflammation, the first stage, lasts approximately 14 days.  During the vascularization 
stage, capillaries begin extension throughout the graft.  From days 14-21, the 
osteoinduction stage occurs concurrently with the vascularization stage, and results in 
osteoblast differentiation. The fourth stage, osteointegration, occurs as bone grows into 
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the graft over the course of several months.  Finally, remodeling occurs over a period of 
months to years.  
BMPs are cytokines which are members of the TGF-β superfamily of proteins.  
BMPs are involved in cell proliferation, differentiation, apoptosis and morphogenesis 
(37).  The hallmark of BMPs is the ability to enhance osteoinduction in a multi-faceted 
approach. BMPs can contribute to osteoinduction via Smad-mediated gene expression 
after interaction with membrane bound BMP receptors.  BMPs act as a chemotactic 
agent by facilitating progenitor cell migration to the graft interface.  BMPs act as growth 
factors by stimulating stem cell proliferation and angiogenesis.  BMPs act in 
differentiation by inducing stem cell maturation into chondrocytes, osteocytes and 
osteoblasts.  BMP-2, on which we are focusing Aim 2, is involved in bone and cartilage 
formation during embryogenesis, morphogenesis, and induction of osteogenesis 
(lineage specific differentiation in mesenchymal progenitor cells and osteoblasts) (37).   
In vivo bone formation has been demonstrated in several spinal fusion models 
using BMP-2.  In a rat model, rhBMP-2 has demonstrated up to a tenfold increase in 
ectopic bone formation over bone extract (38-40). In a canine intertransverse fusion 
model, successful bone fusion at 3 months was evident in rhBMP-2 specimen, while no 
fusion was observed with autograft (41, 42).  Dose dependency of BMP-2 for spinal 
fusion has been observed; increased dosages yield more rapid and more significant 
degrees of fusion (42, 43).   
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Current clinically used materials in spinal fusion 
 In response to the inadequacy of autograft for spinal fusion in patient 
populations, several alternative fusion materials have been studied.  Healos (DuPuy 
Spine, Inc) is a Type I collagen/hydroxyapatite matrix provided in sheets.  Healos 
provides no immediate structural support as a fusion mass and is only an 
osteoconductive conduit.  It must be soaked in bone marrow aspirate to achieve 
osteoinductive capabilities.  Healos has been found to achieve clinical outcomes similar 
to autograft; however, Healos yields a fusion mass that is radiologically inferior to 
autograft (44). 
 Calcium sulfate pellets (OSTEOSET, Wright Medical Technologies) are another 
material that has been studied as an autograft replacement for spinal fusion.  This is a 
resorbable, osteoconductive material. In a study in which one side of the spine was 
augmented with iliac crest autograft and the other side was augmented with 
OSTEOSET, there was no significant difference in fusion between sides (45).   
 Coralline hydroxyapatite has also been assessed clinically for spinal fusion 
procedures.  Although this material was found to promote bone growth, in an 
posterolateral intertransverse fusion study it was found that there is not enough local 
bone available in this procedure to produce fusion comparable to autograft (46). 
rhBMP-2 has been tested in several completed, prospective, randomized clinical 
trials which have resulted in FDA approval for use in anterior interbody spinal fusion (47, 
48).  Carriers for BMP-2 used in clinical trials and/or animal studies include Gelfoam, 
biphasic ceramic phosphates (hydroxyapatite + tricalcium phosphate) (49), 
hydroxyapatite granules (50), an artificial hydroxyapatite True Bone Ceramic (9, 51), or 
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β-tricalcium phosphate mixed with a polymer matrix (52). While many studies utilize 
levels of BMP-2 loading in the 0.1 to 5 mg range, some studies, such as those by 
Namikawa have demonstrated success in spinal fusion with loading of less than 100 µg 
of BMP-2 per 3 cc of material (52).   
OP-1 (rhBMP-7) is a growth factor that has been approved for clinical use in 
spinal fusion for symptomatic degenerative spondylolisthesis and spinal stenosis.  OP-1 
is applied as putty with carboxymethylcellulose and bovine collagen.  In a clinical study 
using OP-1 for fusion in patients with lumbar degenerative spondylolisthesis, the OP-1 
putty yielded fusion in 70% of patients (53, 54).  However this was not statistically 
different from autograft controls.  In another study involving the use of OP-1 for 
posterolateral intertransverse fusion in patients with degenerative spondylolisthesis with 
spinal stenosis, but fusion was only seen in 4 or 7 patients (in comparison to 7 or 9 
patients who received the control, autograft, hydroxyapatite,TCP) (55). 
 
Significance of the study 
 The photocurable polyanhydride system has numerous advantages for 
applications in spinal repair.  First, the photocurable nature of the system, by virtue of 
methacrylate groups, allows formation of the network in situ, such that the polymer fits 
perfectly into the desired region.  Second, upon crosslinking, the network forms with a 
mechanical strength sufficient to withstand the compressive forces of the spinal column.  
Since the material’s modulus is comparable to that of cortico-cancellous bone, it is less 
likely to shield the bone from normal stresses.   Next, the system versatility is clearly 
unique.  The ratios of monomers can be altered to fit nearly any degradation rate.  
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Additionally, up to 30 wt% of the formulation can consist of reactive and nonreactive 
additives (inorganic fillers or porogens, growth factors, or viscosity modifiers) without 
altering crosslinking kinetics.  Photocuring allows a more extensive handling time prior 
to crosslinking than is typically possible with chemical crosslinking (as in PMMA). 
Finally, system biodegradability eliminates the need for secondary surgeries to remove 
the device. 
 Development of this photo-curable poly(anhydride) system into an 
osteoconductive, osteoinductive biomaterial for use in spinal applications will be a 
paradigm shift from the current material of choice,  autograft harvested from iliac crest.  
In summary, the research detailed in this dissertation provides a major advance in 
osteoconductive, osteoinductive biomaterials for use in spine applications.  These 
studies will also generate data supporting the capability of this material for sustained 
release of proteins. The results from this study will lead to the development of an 
osteoinductive (through sustained release of BMPs), degradable, in situ curable 
material in spinal fusion applications. 
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Abstract 
 In the past decade, injectable biomaterials that are capable of in situ formation 
have garnered increased interest for use in restorative orthopedic procedures.  In this 
study, the in vitro degradation of photocrosslinked polyanhydride matrices, derived from 
methacrylic anhydrides of 1,6-bis(p-carboxyphenoxy)hexane (MCPH) and sebacic acid 
(MSA) were evaluated over a six-week period under physiological conditions. These 
matrices were augmented with two additives – the reactive diluent polyethylene glycol 
diacrylate (PEGDA) and the buffering agent calcium carbonate (CaCO3).    Disc shaped 
specimens were produced by crosslinking the components using both chemical and 
photoinitiators and exposure to visible light.  The experimental variables studied 
included: MCPH:MSA ratio, PEGDA molecular weight and weight fraction,  and 
incorporation of CaCO3.  The effects of these variables on local pH, water uptake, mass 
loss, and mechanical properties were explored.  Increasing the MCPH:MSA ratio 
decreased the mass loss and water uptake at predetermined endpoints, and decreased 
buffer acidity during degradation.  Both PEGDA and CaCO3 were found to decrease 
acidity and to reduce water uptake during degradation.  Incorporation of CaCO3 enabled 
maintenance of compressive modulus during degradation.  These results demonstrate 
that incorporation of reactive diluents and nonreactive additives into networks of 
photocrosslinked anhydrides can improve system properties as a material for bone 
replacement. 
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Introduction
Polymers have been explored for augmentation and/or regeneration of osseous 
tissue – including pins and plates in fracture fixation, fillers for long bone defects, and 
spinal augmentation.  An ideal polymeric biomaterial for these applications provides 
immediate mechanical stability, degrades over time in order to promote new bone 
growth, and promotes no adverse immune response.  To fulfill these three criteria, the 
following characteristics are desired for bone regenerative biomaterials: capability of in 
situ formation, conformability to the implantation site, controlled degradation and 
retention of mechanical characteristics.  Additionally, the material should be readily 
modifiable to include osteogenic factors or components which minimize local pH 
alterations, as local acidity can induce inflammation and impair bone healing (1).  This 
combination of features is ideal for complex fractures, bony defects, or spinal 
augmentations which require immediate mechanical support yet would benefit from 
material degradation and eventual replacement by bone.   
The well-characterized homo and co-polymers of α-hydroxy acids (PHAs) such 
as poly(lactic acid) and poly(glycolic acid), which have great utility as surgical sutures, 
have garnered the most attention amongst biocompatible, degradable polymers.  In 
fracture fixation and bone augmentation applications, solid rods, plates and membranes 
formed from the PHAs have been used in conjunction with bioactive glass for evaluation 
of osteoconductivity (2).  While the PHAs do initially possess sufficient mechanical 
strength for load-bearing applications, their bulk degradation mechanism results in a 
rapid loss of strength without accompanying loss of mass.  Additionally resultant from 
the degradation mechanism, the accumulation of hydrophilic degradation products can 
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cause local acidity and inflammation.  Another limitation of the PHA-based systems is 
the inability to be processed and formed in situ, primarily due to an absence of reactive 
moieties or photocurable groups.  PHAs bearing acrylate end groups have been 
synthesized and explored for drug delivery and tissue sealant applications (3); however,  
these polymers lack versatility with respect to degradation behavior.  
Spine-related applications would benefit greatly from the development of 
injectable and in situ curable biomaterials. Spinal fusion is a procedure that eliminates 
or minimizes motion at a site of degeneration in the spinal column.  When fusion 
procedures yield new bone that welds the transverse processes or the vertebral bodies, 
the stability of the spinal column is enhanced without dramatically altering spine motion 
as a whole.  The osteoinductive material of choice for grafting is autograft harvested 
from the iliac crest.  The use of autograft is dictated by limited availability at the donor 
site (4) and post-operative morbidity due to long-term discomfort at the donor site (5).  
Furthermore, in cases of revision procedures and/or when previous iliac crest harvest 
has been made, the autograft option is an untenable one.  These limitations form the 
basis and serve as the motivating elements in the development of synthetic alternatives.  
Many materials are currently being studied for use in spinal fusion including calcium 
sulfate pellets (6), collagen/hydroxyapatite (HA) matrices (7), carriers for BMP-2 
(calcium phosphates (8), HA (9-11), and combinations of calcium phosphate and HA 
(12)), and BMP-7 (OP-1) (13-15). Autograft and the majority of currently studied 
synthetic alternatives do not provide immediate load-bearing capability to the spine. 
Mechanical stability does not occur until a bony fusion mass is formed.  Based on the 
surgical consideration and desired clinical outcomes, the ideal material for spinal fusion 
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applications is a degradable, in situ curable biomaterial that provided mechanical 
support until sufficient new bone growth occurs.  
An anhydride based polymer system has been developed which bears reactive 
methacrylate functionalities that cure rapidly upon exposure to UV or visible radiation to 
produce high strength networks with variable degradative lifetimes (16). This system 
meets the criteria for use in bone regeneration applications and provides an alternative 
synthetic system to overcome the limitations of PHAs, autograft or other materials used 
in spinal fusion.  For example, the system components can be mixed as a paste, which 
can be conformed to the desired region and crosslinked in situ by virtue of methacrylate 
groups.  Furthermore the chemistry of the monomers (differing lipophilicities) offer a 
means of varying the degradation of the system from a few days to around a year 
without compromising the photocuring characteristics by simply changing the co-
monomer composition in the polymer (16, 17). Another perceived advantage of 
polyanhydrides (PAs)  is a degradation mechanism predominantly via surface erosion 
(18), a result of the hydrophobicity of the matrix and degradation products.   For 
example, Muggli et al have shown complete degradation of discs of crosslinked MSA 
(an aliphatic anhydride monomer) in 50 hours, while crosslinked discs of MCPH (an 
aromatic, hydrophobic anhydride monomer) reached only 30% mass loss after 90 days 
of degradation (19).   Surface-eroding materials also favor the retention of mechanical 
strength during the course of degradation. The dense network enables achievement of 
a high strength material immediately following crosslinking.  Tensile modulus changes 
of less than 20% have been seen at up to 50% mass loss in photocrosslinked PA 
systems (16, 19). The surface erosion mechanism also minimizes acidity around the 
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degrading biomaterial, which should favor new bone deposition.  Finally, in in vivo 
applications, photocrosslinked PAs have shown evidence of soft tissue biocompatibility 
(20, 21) as well as a dynamic interface (22) for bone growth and remodeling. 
  An additional benefit of the photocrosslinked PA system is the relative ease with 
which physical characteristics of the system can be modulated (via incorporation of 
additives) without chemical alterations to the monomers.  Studies to date have primarily 
focused on the curing and degradation behavior of PA semi-interpenetrating networks 
(semi-IPN’s).  In one study, Muggli et al evaluated the degradation behavior of semi-
IPNs composed of linear anhydride polymers within a crosslinked network of 
dimethacrylated anhydride monomers (19).  This study demonstrated that addition of a 
linear polymer into the crosslinked network resulted in increased network hydrophobicity 
and a reduction of shrinkage and heat evolution during polymerization.  Burkoth et al 
explored incorporation of lipophilic moieties bearing photoreactive groups such as 
monomethacrylated cholesterol and stearic acid into networks (23).  In this system, both 
photografting and covalent incorporation of the additives decreased the degradation 
rate in comparison to unmodified networks.   
In this study, we evaluated the in vitro degradation behavior of varying 
formulations of MCPH and MSA in the presence or absence of reactive and nonreactive 
additive agents, with specific emphasis on maintenance of network integrity, retention of 
mechanical properties and local pH control.  The reactive diluent poly(ethylene glycol) 
diacrylate (PEGDA) was selected to modulate network crosslinking by virtue of its dual 
reactive acrylate groups.  Fig. 1 shows a photocrosslinking schematic for the anhydride 
monomers and PEGDA.  The inorganic buffering phase calcium carbonate (CaCO3) 
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was selected as a pH buffer to minimize acidity during degradation.  These two 
constituents were easily incorporated into the system prior to crosslinking. Since one-
dimensional degradation best enables characterization of surface erosion, most studies 
of photopolymerizable anhydrides evaluate crosslinked discs which are typically 12-16 
mm in diameter and <2 mm in height.  Since this does not approximate the three-
dimensional nature of most in vivo situations, in this study, samples of dimensions 8 mm 
diameter, 4 mm height were studied.  The overall effect of each additive (PEGDA or 
CaCO3) was based on criteria for usage of the material in spinal augmentation 
applications - curing efficiency, degradation rate, water uptake, pH during degradation, 
and mechanical properties.  The objectives of this study therefore was to deduce the 
effects of these additives on 1) network water uptake and mass loss, 2) acidity during 
degradation, and 3) maintenance of mechanical strength and integrity during 
degradation to enable the identification of an optimal system for spinal fusion 
applications.  
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n = 6, MCPH
PEGDA
Photoinitiator/
UV/Visible Light
Fig. 1: Photopolymerization scheme for dimethacrylated and diacrylated 
monomers.  MSA - sebacic acid dimethacrylate, MCPH - 1,6-bis(p-
carboxyphenoxy)hexane dimethacrylate, PEGDA – poly(ethylene glycol) 
diacrylate. 
 
 
 
Experimental 
 
Materials 
 Methacrylic acid, sebacoyl chloride, triethylamine, methylene chloride, sodium 
bicarbonate, sodium sulfate, 4-hydroxybenzoic acid, 1,6-dibromohexane, methacryloyl 
chloride, poly(ethylene gycol) diacrylate, camphorquinone, ethyl 4-
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(dimethylamino)benzoate, benzoyl peroxide, dimethyl toluidine, n-methyl pyrrolidone, 
sodium chloride, potassium chloride, Tris, sodium phosphate monobasic, magnesium 
chloride, calcium chloride, calcium carbonate, and hydrochloric acid were obtained from 
Sigma-Aldrich. Sulfuric acid and acetone were obtained from Fisher Scientific. All 
chemicals were used as received. 
 
Experimental design 
Effect of incorporation of PEGDA 
In order to assess the effects of the reactive additive PEGDA in photocurable PAs, 15 
sample formulations were evaluated.  Two variables were considered: 1) mass fraction 
of PEGDA in the formulation and 2) ratio of MCPH to MSA.  High, intermediate and low 
levels for each variable were selected, and used in a full factorial experimental design.  
Three mass fractions of PEGDA were evaluated – 0%, 5%, 10%, 20% and 40 w/w %.  
Three MCPH:MSA ratios were evaluated – 30:70, 50:50, and 70:30. The values for all 
parameters and all combinations can be seen in Table 1 (a) and (b). 
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Table 1: PEGDA MW 700, MSA, and MCPH experimental design 
a. Levels of parameters tested in the experimental design 
wt % PEGDA MCPH:MSA ratio 
Low level (0) 0% Low level (0) 30:70 
Low intermediate level (1) 5% Intermediate level (1) 50:50 
Intermediate level (2) 10% High level (2) 70:30 
High intermediate level (3) 20%   
High level (4) 40%   
b. Combinations of the experimental levels and parameters in the full factorial 
design 
Formulation wt% PEGDA MCPH:MSA ratio 
F00 0% 30:70 
F01 0% 50:50 
F02 0% 70:30 
F10 5% 30:70 
F11 5% 50:50 
F12 5% 70:30 
F20 10% 30:70 
F21 10% 50:50 
F22 10% 70:30 
F30 20% 30:70 
F31 20% 50:50 
F32 20% 70:30 
F40 40% 30:70 
F41 40% 50:50 
F42 40% 70:30  
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An additional variable, PEGDA molecular weight, was also assessed.  Two 
PEGDA molecular weights were evaluated - MW 575 and MW 700.  The values for all 
parameters and all combinations for the MW 700 experiments can be seen in Table 1 
(a) and (b).  The values for all parameters and all combinations for the MW 575 
experiments can be seen in Table 2 (a) and (b). 
Effect of incorporation of CaCO3   
In order to assess the effects of the nonreactive additive CaCO3 in photocurable 
PAs, four sample formulations were evaluated.  Three variables were considered: 1) 
presence or absence of CaCO3, 2) ratio of MCPH to MSA, and 3) presence or absence 
of PEGDA. High and low levels were selected for each parameter, and used in a full 
factorial experimental design. The values for all parameters and all combinations for the 
CaCO3 experiments can be seen in Table 3 (a) and (b). 
 
Monomer synthesis 
Sebacic acid dimethacrylate 
Sebacic acid dimethacrylate (MSA) was synthesized from methacrylic acid and 
sebacoyl chloride as described by Tarcha (24).  Methacrylic acid (9 g) and triethylamine 
(Et3N) (11.63 g) were dissolved in methylene chloride (150 ml), and the mixture was 
stirred at 0°C for 30 min. Sebacoyl chloride (12.5 g) was added dropwise to the solution. 
Stirring was continued for 1 h at a reduced temperature, followed by vacuum filtration 
for removal of the precipitated triethyl ammonium chloride. The filtrate was diluted with 
an additional 100 mL of methylene chloride and cooled to 0°C. The solution was 
washed sequentially with saturated NaHCO3  
 31
 
T able 2: PEGDA MW 575, MSA and MCPH experimental design 
a. Levels of parameters tested in the experimental design 
wt% PEGDA MCPH:MSA ratio 
Low level (0) 0% Low level (0) 30:70 
Intermediate level (1) 20% Intermediate level (1) 50:50 
High level (2) 40% High level (2) 70:30 
b. Combinations of the experimental levels and parameters in the full factorial 
design 
Formulation wt% PEGDA MCPH:MSA ratio 
P00 0% 30:70 
P01 0% 50:50 
P02 0% 70:30 
P10 20% 30:70 
P11 20% 50:50 
P12 20% 70:30 
P20 40% 30:70 
P21 40% 50:50 
P22 40% 70:30 
 
 
 
Table 3: CaCO3, MSA, MCPH, and PEGDA experimental design 
a. Low, intermediate, and high levels tested in the factorial design 
 wt% CaCO3 MCPH:MSA ratio wt% PEGDA 
Low level 0% 30:70 0% 
High level 20% 50:50 20% 
b. Combinations of the experimental values in the full factorial design 
Formulation wt% CaCO3 MCPH:MSA ratio wt% PEGDA 
F00 0% 30:70 0% 
F03 0% 30:70 20% 
F13 0% 50:50 20% 
F10 0% 50:50 0% 
C00 20% 30:70 0% 
C01 20% 50:50 0% 
C30 20% 30:70 20% 
C31 20% 50:50 20%  
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(250mL × 2) and distilled H2O (250mL × 2) and dried over Na2SO4. Methylene chloride 
was then removed in vacuo at 0°C.  
1,6-bis(p-carboxyphenoxy)hexane 
 1,6-bis(p-carboxyphenoxy)hexane (CPH) was synthesized from 4-
hydroxybenzoic acid and 1,6-dibromohexane based on the synthesis of 1,3-bis-(p-
carboxyphenoxy)propane described by Conix (25).  NaOH (20 g) was dissolved in 
distilled water (100 ml) in a 500 ml round-bottom flask equipped with a reflux condenser, 
an addition funnel and a stirbar.  To this solution, 4-hydroxybenzoic acid (29 g) was 
added, and the system was heated until reflux. 1,6-dibromohexane (24.6 g) was added 
dropwise over 2 hours.  The reaction was stirred for several hours under reflux.  The 
product (disodium salt of CPH) was dried by vacuum filtration and washed twice with 
methanol. The product was dissolved in distilled water, warmed to 60°C and acidified to 
pH 2 with H2SO4.  This resulted in the free acid of CPP or CPH as a white frothy 
precipitate.  The product was then isolated by vacuum filtration and washed with 
distilled H2O (200 ml × 2) and acetone (200 ml × 2) to remove any trace organics, 
water, and unreacted 4-hydroxybenzoic acid.  The final product was then dried 
overnight in a 60°C oven. 
1,6-bis(p-carboxyphenoxy)hexane dimethacrylate 
1,6-bis(p-carboxyphenoxy)hexane dimethacrylate (MCPH) was synthesized from 
CPH and methacryloyl chloride as described by Tarcha (24).  1,6-bis(p-
carboxyphenoxy)hexane (11.3 g) and Et3N (8.08 g) were dissolved in methylene 
chloride (120 mL) and stirred at 0 °C for 45 min. Methacryloyl chloride (7.1g) was added 
dropwise to this solution. Stirring was continued at a reduced temperature for 3.5 h, 
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followed by vacuum filtration for removal of precipitated triethyl ammonium chloride. The 
filtrate was washed sequentially with saturated NaHCO3 (200 mL × 2) and distilled H2O 
(200 mL × 2). The solution was dried over anhydrous Na2SO4, and CH2Cl2 was 
removed in vacuo; a slurry was thereby produced. Then, anhydrous ethyl ether was 
added and removed in vacuo to facilitate the removal of any remaining methylene 
chloride. 
 
Sample preparation and photopolymerization 
Photopolymerizations were initiated with a dual initiator strategy, composed of 
camphorquinone (CQ)/ ethyl 4-(dimethylamino)benzoate (4-EDMAB) for light-initiated 
crosslinking, and benzoyl peroxide (BPO)/dimethyl toluidine (DMT) for chemically-
initiated crosslinking.  Sample formulations were prepared by thoroughly mixing the 
monomers in appropriate amounts, followed by adding an appropriate quantity of a 
BPO/CQ in N-methyl pyrrolidone (NMP) followed by 4-EDMAB/DMT in NMP to yield a 
final quantity of up to 0.1 wt% for each of CQ, BPO, 4-EDMAB, and DMT in the 
formulation.  Uniform discs (4 mm in height and 8 mm in diameter) were prepared in 
Teflon molds Samples were polymerized with a blue dental lamp (3M CuringLight 
XL1500). 
 
Simulated body fluid preparation 
 Simulated body fluid (SBF), first described by Kokubo (26), was prepared by ion 
concentrations nearly equivalent to the inorganic components of human plasma – 142 
mM Na+,  5 mM K+, 1.5 mM Mg2+, 2.5 mM Ca2+, 148.8 mM Cl-, 4.2 mM HCO2-, and 1 
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mM SO42-, buffered with 50 mM Tris.  Bayraktar’s modifications to Kokubo’s SBF were 
used in this study (27).   
 
In vitro degradation studies 
In vitro degradation parameters were assessed in simulated body fluid (SBF), pH 
7.4 at 37°C to most thoroughly mimic physiological conditions.  Samples were 
maintained at 60 rpm on an orbital shaker throughout degradation studies.  The discs 
were degraded in seven ml of SBF.  Buffer was replaced daily for the first two weeks, 
every other day for the next two weeks, and once every three days for the last two 
weeks of the study to maintain sink conditions.  Buffer pH was measured and recorded 
at each timepoint prior to buffer exchanges.  At pre-selected time points (2 and 6 
weeks), four samples of each formulation were removed for assessment.   
 
Gravimetric analysis 
 The dry mass of the samples (m0) was measured prior to commencement of 
degradation studies in SBF.  At pre-determined time points, samples were removed, 
rinsed with PBS and the excess liquid dabbed using a Kimwipe® before recording their 
wet mass (mw).  Samples were then flash frozen in liquid nitrogen and freeze-dried 
overnight. Next, they were vacuum-dried for an additional 48 hours and weighed to 
obtain the dry mass after degradation (md).  The mass loss (ML, Eq. 1) and water 
uptake (WU, Eq. 2) of the samples were then determined by the following equations: 
0
0
m
mmML d−=
                                                          (1) 
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m
mmWU −=
                                                         (2) 
Minimums of four (n =4) samples were measured for each composition and time point. 
 
Mechanical testing 
Compressive mechanical testing was conducted using an AGS-J mechanical tester 
(Shimadzu, Kyoto, Japan) with a 1 kN load cell on dried samples (n = 4). The cylinders 
were compressed between two plates moving at a crosshead speed of 1 mm/min until 
failure, while load and displacement was recorded throughout. Based on sample 
geometry, the stress versus strain behavior was obtained and plotted. The compressive 
modulus was determined from the stress-strain curve using Trapezium software 
(Shimadzu) and Microsoft Excel. 
 
Scanning electron microscopy 
 Dried PA samples before and after degradation were cryo-fractured by cooling in 
liquid nitrogen and the cross-section was analyzed using scanning electron microscopy 
(SEM). The pellets were sputter-coated with gold-palladium to minimize charging and 
then mounted onto aluminum stubs using conductive tape for imaging. SEM images 
were obtained using a Hitachi S-4200 SEM at an acceleration voltage of 5 keV. 
 
Statistical analysis 
Results are reported as mean ± standard deviation.  Data analysis was 
performed using SigmaStat version 3.1 and SigmaPlot version 9.0 (Systat Software, 
Inc. Point Richmond, CA, USA). To determine differences between time points for each 
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formulation, a one-way analysis of variance (ANOVA) or a non-parametric ANOVA 
(Kruskal-Wallis Test) was first performed to determine statistical significance (p < 0.05) 
within each data set.  When the analysis of variance detected significance, a Tukey 
Multiple Comparison Test (one-way ANOVA) or a Dunn’s Multiple Comparison Test 
(Kruskal-Wallis Test) was run with a confidence level of 95%.  To determine differences 
between different formulations at the two timepoints, a t-test or a Mann-Whitney Rank 
Sum Test was performed to determine statistical significance (p<0.05).  In addition to 
statistical analysis by ANOVA, the main effects of experimental parameters 
(MCPH:MSA ratio, PEGDA amount, CaCO3 amount) on mass loss and water uptake 
were calculated at each timepoint as enabled by the factorial experimental design (28). 
 
Results 
 
 
Nomenclature 
 Polymer formulations are described in the following manner.  For the samples 
containing PEGDA MW700, the formulations are defined as F(x)(y) where x refers to the 
wt% of PEGDA with 0=0%, 1=5%, 2=10%, 3=20%, and 4=40% and y refers to the 
MCPH:MSA ratio where 0=30:70, 2=50:50, and 3=70:30. For the samples containing 
PEGDA MW575, the formulations are defined as P(x)(y) where x refers to the wt% of 
PEGDA with 0=0%, 1=20%, and 2=40%, and y refers to the MCPH:MSA ratio where 
0=30:70, 2=50:50, and 3=70:30.  Finally, samples containing CaCO3 were described by 
the notation C(x)(y) where the C denotes the presence of CaCO3 at 20 wt%, x 
represents the wt% of PEGDA, with 0=0% and 3=20% (to correspond with the 
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respective F formulations) and y represents the MCPH:MSA ratio with 0=30:70 and 
1=50:50. 
 
General observations 
In order to maximize the impact of the experimental variables, a more efficient 
dual initiator curing system was explored.  Instead of only a conventional 
photoinitiator/accelerator system commonly used in photocrosslinking applications, this 
system was augmented with a chemical curing agent and accelerator (benzoyl 
peroxide/dimethyl toluidine).  By combining these two systems, the initiator 
concentration required for induction of polymerization was 10-fold lower.  The low 
initiator concentrations allowed longer working times of the paste than were previously 
enabled.  However, more importantly, the addition of chemical curing resulted in rapid 
photocrosslinking (~ 60-90 seconds) with excellent depth of cure (up to 10 mm).   
 Some formulations did not maintain network integrity during the course of the in 
vitro degradation.  These formulations included the 40% PEGDA MW 700 formulations 
(F40, F41, F42), the 40% PEGDA MW 575 formulations (P20, P21, P22), and most of 
the 20% PEGDA MW 575 formulations (P10, P11). These results suggest an upper limit 
for PEGDA wt% within the matrices. 
 
pH profiles 
 To evaluate the acidity as a result of the polymer degradation products, pH of the 
degradation buffer was measured prior to each buffer exchange.  The degradation 
buffer was exchanged daily for the first week of degradation, every other day for the 
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next two weeks, and every third day for the final two weeks.  The pH profiles for each 
formulation showed the same general shape.  During days one and two there was a 
dramatic drop in degradation buffer pH.  From days three to 14, the pH level slowly 
increased to a level near 7.4 (the initial degradation buffer pH).  At day 14, when 
degradation buffer exchanges were changed from daily to every other day, there is an 
initial drop in pH.  This drop gradually recovered over the next few days.  By day 40, the 
pH for all samples was approaching 7.4. 
 Selected pH profiles are shown in Fig. 2 to demonstrate trends based on 
formulation.  As expected based on degradation rates reported in other studies (16), an 
increase in MCPH:MSA ratio resulted in decreased acidity during the course of 
degradation.  This trend was seen in both unmodified formulations (without PEGDA), 
shown in Fig. 1A, and in formulations containing PEGDA.  Additionally, as shown in Fig. 
2B, the inclusion of PEGDA in the crosslinked network resulted in a net decrease in 
acidity in a dose dependant manner.  While the intermediate levels of PEGDA (5 and 10 
wt%), were not dramatically different in pH response, the high level of PEGDA (20%) 
caused less buffer acidity during degradation and the formulations without PEGDA 
resulted in increased buffer acidity during degradation.  During the first 30 days of 
degradation, the degradation buffer of formulations containing PEDGA MW 575 was 
less acidic than formulations containing PEGDA MW 700.  However, after 30 days there 
was negligible difference in the pH response of the formulations.  Both formulations 
were less acidic than unmodified formulations.  The pH profiles for these formulations 
are shown in Fig. 2C. 
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 The addition of CaCO3 to sample formulations provided the most dramatic 
decrease in degradation buffer acidity during sample degradation, shown in Fig. 2D.  
Formulations with CaCO3 or CaCO3 + PEGDA exhibited the least acidity of any 
formulation; however, these formulations were not different from each other.  In 
comparison, the unmodified samples exhibited the most acidic degradation buffer, while 
the samples containing PEGDA alone had intermediate buffer pH levels. 
 
Gravimetric analysis 
Mass loss 
 Percent mass loss was determined after two and six weeks of in vitro 
degradation to assess the extent of erosion that occurred in photocrosslinked PA 
networks (Fig. 3).  In general, a statistically significant difference in mass loss between 
weeks two and six was seen only in the samples containing 0% PEGDA (F00, F01, 
F02) and two samples containing 5% PEGDA (F11 and F12).  Likewise, samples 
containing 10% or 20% PEGDA did not exhibit statistically significant changes in mass 
loss between two and six weeks.  In general, samples containing PEGDA underwent 
less change in mass than samples without PEGDA.  In addition, samples with a higher 
MCPH:MSA ratio exhibited less mass loss than samples with a lower MCPH:MSA ratio.   
The main effects of each parameter (CaCO3, MCPH:MSA ratio, PEGDA) on mass loss 
are summarized in Fig. 4.  When CaCO3 is increased from a low level (0%) to a high 
level (25%) mass loss was increased.  This effect was more pronounced after two 
weeks of degradation than after six weeks.  Increasing the MCPH:MSA ratio from a low 
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level (30:70) to a high level (50:50), resulted in a decrease in mass loss.  Altering 
PEGDA content from a low level (0%) to a high level (20%) also decreased mass loss. 
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Fig. 3: Percent change in polymer mass during in vitro degradation for 
unmodified photocrosslinked anhydride networks (F00, F01, F02), 
photocrosslinked anhydride networks contained PEGDA MW700 (F10 – 
F32) or MW575 (P11), photocrosslinked anhydride networks containing 
CaCO3 (C00, C01) or photocrosslinked anhydride networks containing 
CaCO3 and PEGDA MW700 (C30 and C31). Results are presented as 
means ± standard deviation for n = 3-4. 
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Fig. 4: Main effects of CaCO3 incorporation, PEGDA incorporation, and 
MCPH:MSA ratio percent on mass loss of photocrosslinked anhydride 
networks for 2 and 6 weeks. A positive number indicates that the 
particular parameter had an increasing effect on the mass loss as the 
value was changed from a low (L) level to a high (H) level. A negative 
number indicates a decrease in the normalized cumulative mass loss as 
the parameter was changed from the low (L) level to a high (H) level.  
Formulations described in Table 1 were used for this analysis.  Error bars 
represent the standard deviations of the effect. 
 
 
 
Water uptake 
Percent water uptake was determined after two and six weeks of in vitro 
degradation (Fig. 5).   All samples exhibited a greater percent water uptake at 6 weeks 
than at 2 weeks (p<0.02 for all formulations).  After two weeks of degradation, within a 
given MCPH:MSA ratio, samples containing any weight percent of PEGDA exhibited 
significantly less water uptake than the samples without PEGDA (p<0.001). After six 
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weeks of degradation, there was a statistically significant difference in water uptake 
between all formulations except between F10 and F20, and F20 and F30.  Increasing 
the PEGDA content of the photocrosslinked networks decreased the water uptake 
during in vitro degradation.  Dose-dependency of this effect was not seen after two 
weeks of degradation, but was evident after 6 weeks of degradation.  A trend was also 
seen to correlate MCPH:MSA ratio with water uptake.  In general, an increase in 
MCPH:MSA ratio (within a given PEGDA weight percent) resulted in a decrease in 
water uptake during degradation. 
The main effects of each parameter (CaCO3, MCPH:MSA ratio, PEGDA content) 
on water uptake are summarized in Fig. 6.  Changing CaCO3 content from a low level 
(0%) to a high level (25%) resulted in increased water uptake after two weeks of 
degradation. Alternatively, the same increase in CaCO3 content resulted in decreased 
water uptake after six weeks of degradation. Increasing the MCPH:MSA ratio from a low 
level (30:70) to a high level (50:50), resulted in a decrease in water uptake.  Altering 
PEGDA content from a low level (0%) to a high level (20%) also decreased water 
uptake. 
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Fig. 5: Percent water uptake during in vitro degradation for unmodified 
photocrosslinked anhydride networks (F00, F01, F02), photocrosslinked 
anhydride networks containing PEGDA MW700 (F10 – F32) or MW575 
(P11), photocrosslinked anhydride networks containing CaCO3 (C00, 
C01) or photocrosslinked anhydride networks containing CaCO3 and 
PEGDA MW700 (C30, C31). Results are presented as means ± standard 
deviation for n = 3-4. 
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Fig. 6: Main effects of CaCO3 incorporation, PEGDA incorporation, and 
MCPH:MSA ratio on percent water uptake of photocrosslinked anhydride 
networks for 2 and 6 weeks. A positive number indicates that the 
particular parameter had an increasing effect on the water uptake as the 
value was changed from a low (L) level to a high (H) level. A negative 
number indicates a decrease in the normalized cumulative water uptake 
as the parameter was changed from the low (L) level to a high (H) level.  
Formulations described in Table 3 were used in this analysis.  Error bars 
represent the standard deviations of the effect. 
 
 
 
Scanning electron microscopy 
 Formulations that did not contain CaCO3 showed no microporosity at the 
degrading zone.  In contrast, as seen in Fig. 7, microporosity is evident in samples 
containing 20 wt% CaCO3 in the region of the degradation front.  The degradation front 
for samples with CaCO3 was significantly thicker than the relatively thin front of 
degradation for samples without CaCO3 (data not shown). 
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 Mechanical testing 
 Compressive mechanical testing was performed on freeze-dried samples that 
were not subjected to degradation and those that had been subjected to either two or 
six weeks of in vitro degradation.  As seen in Fig. 8, inclusion of CaCO3 enabled 
maintenance of compressive modulus during in vitro degradation in comparison to 
samples which did not contain CaCO3.  Although samples with or without CaCO3 had a 
similar compressive modulus prior to degradation,  after two weeks of degradation, 
samples containing CaCO3 had a significantly greater compressive modulus (104±12 
MPa) than samples without CaCO3 (68±14 MPa) (p=0.015).  Interestingly, after six 
weeks of degradation samples containing CaCO3 had a compressive modulus of 127±9 
MPa, which is greater than the compressive modulus prior to degradation or after only 
two weeks of degradation.  After six weeks of degradation, samples without CaCO3 
underwent further loss of compressive modulus to 21±3 MPa (p<0.01). 
 
Fig. 7: SEM images of the front of degradation for a photocrosslinked 
polyanhydride network (A) and for a photocrosslinked poly(anhydride) network 
containing 20 wt% CaCO3 (B).   
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Discussion 
Many orthopedic applications can benefit from the development of a high-
strength, degradable, in situ curable polymeric system.  Criteria for success as a bone 
regenerative material include: capability of in situ formation, conformability to the 
implantation site, controlled degradation (water uptake and mass loss) and retention of 
mechanical characteristics.  Additionally, the degradation of the material should 
minimally affect local pH. In recent years a family of photopolymerizable anhydride 
network systems based on difunctional methacrylated monomers derived from sebacic 
anhydride, 1,3-bis(p-carboxyphenoxy)propane, and 1,6-bis(p-carboxyphenoxy)hexane 
have been developed (16) and explored for tissue contacting and drug delivery 
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applications.  These difunctional moieties can be crosslinked upon exposure to UV or 
visible light in the presence of a photoinitiator.  The photocurable nature of the system 
fulfills two desirable characteristics for a bone regenerative material – namely in situ 
formation and conformability to an implantation site or three dimensional mold (16).   
The incorporation of PEGDA was expected to promote the crosslinking efficiency 
of the system at the expense of increased network hydrophilicity and water uptake.  
Surprisingly, PEGDA incorporation into the photocrosslinked PA system resulted in a 
dramatic decrease in water uptake during degradation.  This phenomenon occurred in a 
somewhat dose-dependent fashion; with even 5 wt% PEGDA incorporation resulting in 
a 10-fold decrease in water uptake after six weeks of degradation (see Fig. 5).  
Increases in PEGDA concentrations to 10 or 20 wt% further decreased water uptake at 
a modest level.  The reduction of water uptake was seen in all formulations regardless 
of MCPH:MSA ratio or the inclusion of CaCO3.  This observation was contrary to the 
initial premise that inclusion of PEGDA would result in increased water uptake by nature 
of the molecule’s hydrophilicity.  Excessive system water uptake or swelling is 
undesirable, as it would preclude adequate filling of a void in vivo and would adversely 
affect the rate of degradation.  The most likely cause of the decrease in water uptake for 
the PEGDA-containing formulations is the presence of a denser network with increased 
crosslinking that minimizes water uptake.  Additionally, the introduction of PEGDA likely 
reduces the concentration of unreacted monomer that can lead to autocatalytic events 
promoted by the hydrolysis of the monomers.  PEGDA may be a useful additive for 
modulating water uptake behavior in in vivo applications for photocrosslinked PA 
networks. 
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Interestingly, CaCO3 inclusion also affected the water uptake behavior of degrading 
matrices (see Fig. 5).  Samples containing both PEGDA and CaCO3 displayed similar 
water uptake behavior as comparable formulations (same MCPH:MSA ratio) containing 
only PEGDA. However, in anhydride matrices augmented with only CaCO3 significantly 
different water uptake behavior was observed. After two weeks of degradation, the 
presence of CaCO3 resulted in slightly increased water uptake, presumably a direct 
result of microporosity induced by the presence of the additive.  The microporosity 
induced in the region of the degradation front facilitated water influx. Alternatively, after 
six weeks of degradation, the water uptake of samples containing CaCO3 was 
significantly decreased in comparison with corresponding formulations without CaCO3.  
This phenomenon suggests some ionic interaction between the crosslinked network and 
the CaCO3 that effectively tightens the network.  This mechanism may be similar to the 
effects seen during ionotropic gelation of alginate by divalent cations (29).  Crosslinking 
of alginate with calcium chloride serves to stiffen the polymer and to reduce solvent 
swelling (30); a similar effect as is seen in PA networks modulated with CaCO3.  
Modulation of photocrosslinked PAs with CaCO3 may be useful for eliminating longterm 
water uptake in in vivo applications. 
One additional property of importance in the development of a material for use in 
spinal applications is mechanical strength.  The compressive modulus was similar for all 
formulations prior to degradation.  However, after degradation, the compressive 
modulus for formulations without CaCO3 (regardless of PEGDA content) significantly 
decreased (see Fig. 8).  A 25% loss of modulus was seen after two weeks of 
degradation, and a 60% loss of modulus was seen after six weeks of degradation.  In 
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contrast, formulations containing CaCO3 (regardless of PEGDA content) displayed 
maintenance of modulus throughout the six week degradation period.  The mechanism 
for the maintenance of mechanical strength is most likely the ionotropic effect proposed 
as the mechanism for decreasing water uptake in the longterm. Interactions between 
the anhydride network and Ca2+ strengthen the system, which will prove critical for load 
bearing applications in the spine. 
Another important and surprising outcome of the incorporation of PEGDA was 
the reduction in buffer acidity during sample degradation.   During the final four weeks of 
degradation, PEGDA incorporation significantly reduced acidity in the sample 
degradation buffer, with pH differences between samples containing PEGDA and 
samples without PEGDA of ~0.5 pH units (see Fig. 2B).  This elevation in pH was 
greater than would occur purely by a reduction in concentration of anhydride bonds.  
Additionally, PEGDA of a lower molecular weight favored less changes in pH during the 
first 30 days of degradation (see Fig. 2C), an observation that is consistent with a 
denser network (decreased elasticity).  A portion of this effect is dictated by the amount 
of PEGDA measured as a weight percent instead of a mole percent – with this 
measurement, there are more molecules of PEGDA MW 575 in the system with an 
equal weight percent.   Again, with pH differences near 0.5 pH units, it seems unlikely 
that the molar difference can account completely for the reduction in acidity. Although 
PEGDA has been incorporated into a variety of degradable polymers, similar pH effects 
have not been reported. 
Although the incorporation of CaCO3 into the PA matrices did not significantly 
impact the initial drop in pH observed in all samples, the pH of the degradation buffer of 
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samples containing CaCO3 was restored to physiological pH by day 20.  Such a 
normalization of pH was not observed in samples without CaCO3.    Interestingly, 
formulations containing both CaCO3 and PEGDA had similar pH profiles to formulations 
containing CaCO3 alone, an effect greater than that of PEGDA alone.  Furthermore, 
while introduction of PEGDA yielded small changes in pH (reduced acidity) in 
comparison to samples containing CaCO3, the incorporation of both yielded similar pH 
profiles as CaCO3 alone.  More importantly, the beneficial effect of CaCO3 was more 
pronounced after two weeks.  This suggests that the events that contributed to acidity in 
the first two weeks are not easily mitigated by simple formulation changes and are 
induced by initial network hydrolysis. The buffering capability of CaCO3 has been 
studied in conjunction with degradable polymers including PLGA(50:50) (31) and 
poly(ortho esters) (32). Additionally, carbonated calcium phosphates as well as CaCO3 
are capable of buffering pH of lactic acid in the physiological range (33). Inclusion of 
CaCO3 into photocrosslinked PA networks enabled pH buffering in the physiological 
range, a property of importance in bone regeneration applications.  
The effect of MCPH:MSA ratio on mass loss, water uptake, and pH was 
consistent with results from previous studies (16, 19).  In the photocrosslinked PA 
system, mass loss and water uptake are functions of network hydrophobicity.  In 
general, MCPH:MSA ratio affects the system degradation in a predictable manner.  
Increases in MCPH:MSA ratio decrease the mass loss (see Fig. 3) and decrease 
system water uptake (see Fig. 5).  Increasing the MCPH:MSA ratio also decreases the 
acidity that occurs during degradation (see Fig. 2A).  This may be attributed to an 
overall increase in hydrophobicity of the system, which would be expected based on 
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chemical structure considerations of MCPH and MSA.  MCPH, with its two aromatic 
groups and long hydrocarbon chain as a backbone, is a much more hydrophobic moiety 
than MSA, with only a shorter aliphatic hydrocarbon backbone.  A more hydrophobic 
system is expected to less readily uptake water, favoring a slower degradation rate. The 
lower aqueous solubility of MCPH in comparison with MSA is also expected to favor 
reduced acidity. 
The inclusion of the additives PEGDA and CaCO3 also affected mass loss in the 
system.  When PEGDA was included in the system, generally a decrease in mass loss 
was observed, which can be attributed to the increased crosslinking density and 
decreased penetration of water in the system.  In addition, some loss of control of the 
degradation rate dictated by MCPH:MSA ratio occured.  The inclusion of CaCO3 in the 
system increased the system mass loss, a result of microporosity introduced by 
leaching of the additive.  This effect was more pronounced after two weeks of 
degradation than after six weeks of degradation.  We theorize that the effect on mass 
loss is less prominent in the long term due to the ionotropic interactions between the 
calcium ion and the crosslinked network. 
 
Conclusions 
In conclusion, the photocrosslinked PA system described here clearly possesses 
necessary characteristics for usage in bone replacement applications. These 
characteristics are enhanced by the inclusion of PEGDA and CaCO3 as additives.  The 
incorporation of additives does not alter the curing ability or formability of the system.   
Incorporation of PEGDA and CaCO3 serve both to decrease water uptake and to 
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modulate local acidity during degradation.  Surprisingly, inclusion of CaCO3 enables 
maintenance of compressive modulus throughout the degradative lifetime of the 
material.  In this study, we have revealed additional mechanisms for tuning material 
properties via incorporation of additive agents to expand the scope and functionality of 
the system. Finally, this study demonstrates that additives can be easily and 
successfully incorporated into photocrosslinked PA networks to address a variety of 
physical characteristics.  In the future, these strategies can be applied to impart 
osteoinductivity to the network by incorporation of growth factors.   
Selection of a polymer formulation for future work is based on several 
parameters determined in this study.  First, we have determined that roughly 20% mass 
loss after six weeks of degradation is an optimal design criterion for use in drug delivery 
and in vivo bone augmentation applications.  This amount of mass loss will provide 
mechanical stability which lasts until a bony fusion mass can be formed, while still 
allowing substantial release of any osteoinductive factors which will be incorporated in 
the matrix.  The samples containing 10% PEGDA (F20, F21, F22) and the samples 
containing CaCO3 and 20% PEGDA (C30, C31) best meet this criteria.  Additionally, 
based on the results of this study, PEGDA and CaCO3 are additives that improve the 
material properties.  Therefore PEGDA (at 10-20 wt%) and CaCO3 (at a maximum of 20 
wt%) will be components of the design criteria for future work in drug delivery and bone 
augmentation. 
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Abstract 
 Injectable delivery systems are attractive as vehicles of localized delivery of 
therapeutics especially in the context of regenerative medicine.  In this study, the 
potential of photocrosslinked polyanhydride (PA) networks as an encapsulation matrix 
for long-term delivery of macromolecules was studied.  The in vitro release of three 
model proteins (horseradish peroxidase (HRP), bovine serum albumin labeled with 
fluorescein isothiocyanate (FITC-BSA), and insulin) were evaluated from cross-linked 
anhydride networks composed of sebacic acid dimethacrylate (MSA), 1,6-bis-
carboxyphenoxyhexane dimethacrylate (MCPH), and poly(ethylene glycol) diacrylate 
(PEGDA), supplemented with calcium carbonate.  The proteins were formulated into 
granules first by dilution with a cyclodextrin excipient through tituration, followed by 
gelatin-based wet-granulation prior to incorporation into the networks.  Protein release 
was quantified over predetermined time periods by activity assay (HRP), fluorescence 
(FITC-BSA), or ELISA (insulin).  All proteins were readily released from the 
photocrosslinked PA networks; however, each protein displayed a unique release 
behavior.   Most importantly, release of protein with retention of activity and antigenicity 
was achieved for durations ranging from one week to over four months.  In general, a 
more hydrophobic network (higher MCPH:MSA ratio) resulted in slower rates of protein 
release.  Incorporation of PEGDA into the matrices was found to be critical for 
maintenance of integrity during degradation and protein release.  These results suggest 
that a photocrosslinked PA system may useful as injectable delivery systems for long-
term delivery of peptides and growth factors in tissue regeneration applications. 
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Introduction 
 Polymers are routinely used in the development of sustained drug delivery 
systems.  Some of the notable examples of polymer-based sustained release systems 
are Lupron Depot, an implantable ethylene-co-vinyl acetate based system for the 
delivery of GnRH agonist, Nutropin Depot, injectable microspheres of poly(α-hydroxy 
acid) for the delivery of recombinant human growth hormone and the Norplant family of 
Silastic-based implantable devices for the delivery of female contraceptives (1, 2).  One 
of the drawbacks of using non-degradable polymer implantable systems is the need to 
excise the implant at the end of use.  Therefore, when long-term systemic or localized 
delivery is sought, implementation of systems derived from degradable polymers is 
desirable; a need currently met by co-polymers of lactic acid and glycolic acid (PLGA).  
Some of the perceived limitations of the PLGA system include reproducibility of release 
behavior, difficulty in readily providing zero-order release and inability to form the 
delivery vehicle in situ.  This last limitation is particularly relevant for tissue regeneration 
applications in which placement of a delivery system within a trauma site and physical 
conformation of the device to the implant site are important prerequisites to promote 
optimal tissue healing.  Linear polymers containing anhydride linkages (polyanhydrides 
(PA)), which are capable of undergoing surface erosion, fulfill some of these criteria by 
achieving predictable near-zero order release.   
In the PA system, the rate of matrix degradation and drug release can be easily 
modulated by simple modification of polymer hydrophobicity via polymer chemistry as 
well as by alterations in fabrication technique, additive components, and/or geometry (3, 
4).  Sustained release from linear PAs has been focused on a variety of drugs including 
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antibiotics (5, 6), local anesthetics (7), hormones (8), heparin (9), and many types of 
small molecules for the treatment of cancers (5, 10-15).  Gliadel®, one of the most 
successful commercially available polyanhydride drug delivery vehicles, delivers BCNU 
(carmustine) directly in the site of surgical resection for treatment of glioblastoma 
multiforme (16, 17). 
While small molecules form the basis for a majority of new therapeutic agents, 
recombinant protein technologies are becoming increasingly prevalent.  Unlike small 
molecules, proteins are complex three-dimensional molecules whose function is 
dependent on structure.  Proteins are susceptible to chemical and physical 
modifications, which may adversely affect both structure and function.  The environment 
of a protein delivery vehicle is therefore a critical parameter for successful long-term 
protein release.  Matrices derived from linear PA have been explored for release of 
insulin (18), trypsin (19), bovine serum albumin (20), FITC-BSA (21), water-soluble 
bone proteins (22), and the neuropeptide TRH (23).  The utility of PA have been further 
improved by recent adaptation.  A polymer system based on anhydride monomers with 
reactive methacrylate functionalities has been developed for use in orthopedic tissue 
repair and regeneration (24). Upon exposure to light radiation, this system can be 
rapidly crosslinked in situ into a high strength degradable network.  Such systems 
address one of the limitations of the PLGA system as they are amenable to minimally 
invasive surgical interventions. In our laboratory, we have shown that a traditional 
photocrosslinked PA system composed of MCPH and MSA can be easily modified with 
additives such as CaCO3 and PEGDA to modulate degradation properties such as 
mass loss, water uptake, pH and mechanical strength with no adverse impact on the 
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crosslinking capabilities of the system (25).  The versatility for additive incorporation 
demonstrated in this study suggests that this system can be further modified to include 
therapeutic macromolecules without affecting crosslinking parameters.  With the 
incorporation and bioactive molecules, the photocrosslinked PA system can serve as an 
injectable delivery system for sustained release.   Although previous studies of the 
photocrosslinked PA system have focused on orthopedic applications, a more general 
application would involve intra-muscular and sub-dermal injectable systems capable of 
long-term delivery of macromolecules.    
While the hydrophobic nature and surface erosion behavior of PAs protects bio-
encapsulants such as proteins from moisture-induced aggregation that can readily 
occur with other polymeric delivery vehicles (such as poly(D,L-lactide-co-glycolide), 
augmentation with secondary protection strategies is imperative to ensure peptide an 
protein stability in photocurable PA systems.  For example, inclusion of sugar-based 
excipients can prevent aggregation of proteins within a polymeric delivery vehicle (26). 
Additionally, inclusion of basic compounds can minimize acidity during degradation of 
the carrier and further enhance protein stabilization (27).  While several studies describe 
the long-term protein release of proteins and growth factors such as BSA, TGF-β1, HRP 
and IGF-1 from photocurable matrices derived from PEGDA exist (28-31) no such 
studies have been undertaken with photocurable PA, with the notable exception of 
plasmid DNA release (32).   
For this study, three model proteins (HRP, FITC-BSA, and insulin) were selected 
for release from photocrosslinked PA networks.  As seen in Table 1, these proteins 
differ in molecular weight, isoelectric point, and detection strategy.  Recently, we 
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developed a dual-purpose photocurable PA system, with optimized degradation 
characteristics and mechanical properties that is suitable as both an autograft extender 
and delivery vehicle for spinal fusion applications (25).  In this study we have 
implemented a protein stabilization strategy previously developed in our laboratory to 
protect proteins from free radicals during polymerization (33), with some minor 
modifications to stabilize and disperse the protein in the PA system developed for the 
spinal fusion application.  The overall objective of this study is therefore, to demonstrate 
the suitability of this system (see Fig. 1) for sustained delivery of peptides and proteins.  
Specifically, we aim to answer the following questions: (1) To what extent can the 
delivery of macromolecules be controlled by the chemistry of photocrosslinked PA 
networks? (2) Do the released proteins maintain activity and/or antigenicity after 
incorporation into and release from the matrix? (3) Can active protein release be 
achieved over a long-term period (>three months)?, and (4)  Can a variety of 
macromolecules with differing physical properties be released from the networks?  By 
answering these questions, the feasibility of the photocrosslinked PA system for the 
long-term delivery of active macromolecules has been established. 
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Fig. 1: A. Schematic of photocrosslinking.  Anhydride monomers (MSA, MCPH), 
PEGDA, CaCO3 and protein granules were mixed to form a paste.  Mixtures were 
photocrosslinked after addition of photoinitiators and exposure to visible light.  B. 
Photocrosslinked discs were subjected to in vitro degradation.  At predetermined 
timepoints, the release buffer was removed and protein release was quantified. 
 
 
 
Table 1:  Physiochemical properties and methods of detection for model proteins. 
Protein MW pI Structural information Detection method 
Insulin 6.7 kDa 5.3 2 subunits, connected by 
disulfides 
ELISA 
HRP 43 kDa 9.0 Disulfides  
Heme group 
Activity assay 
(oxidation of TMB) 
FITC-BSA 67 kDa 4.8 Roughly 54% α-helix Fluorescence (FITC)  
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 Experimental 
 
Materials 
 Methacrylic acid, sebacoyl chloride, triethylamine, methylene chloride, sodium 
bicarbonate, sodium sulfate, 4-hydroxybenzoic acid, 1,6-dibromohexane, methacryloyl 
chloride, poly(ethylene gycol) diacrylate (PEGDA), camphorquinone, ethyl 4-
(dimethylamino)benzoate (4-EDMAB), benzoyl peroxide, dimethyl toluidine, n-methyl 
pyrrolidone, bovine serum albumin fluorescein isothiocyanate conjugate (FITC-BSA), 
bovine insulin, and calcium carbonate were obtained from Sigma-Aldrich. Horseradish 
peroxidase, TMB substrate kits and Coomassie-based Bradford assay kits were 
purchased from Pierce. Rat insulin ELISA kits were obtained from Crystal Chem. 
 
Monomer synthesis 
Sebacic acid dimethacrylate 
Sebacic acid dimethacrylate (MSA) was synthesized from methacrylic acid and 
sebacoyl chloride as described by Tarcha (34).  Methacrylic acid (9 g) and triethylamine 
(Et3N) (11.63 g) were dissolved in methylene chloride (150 ml), and the mixture was 
stirred at 0°C for 30 min. Sebacoyl chloride (12.5 g) was added dropwise to the solution. 
Stirring was continued for 1 h at a reduced temperature, followed by vacuum filtration 
for removal of the precipitated triethyl ammonium chloride. The filtrate was diluted with 
an additional 100 mL of methylene chloride and cooled to 0°C. The solution was 
washed sequentially with saturated NaHCO3 (250mL × 2) and distilled H2O (250mL × 2) 
and dried over Na2SO4. Methylene chloride was then removed in vacuo at 0°C.  
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1,6-bis-carboxyphenoxyhexane 
 1,6-bis-carboxyphenoxyhexane (CPH) was synthesized from 4-hydroxybenzoic 
acid and 1,6-dibromohexane based on the synthesis of 1,3-bis-carboxyphenoxypropane 
described by Conix (35).  NaOH (20 g) was dissolved in distilled water (100 ml) in a 500 
ml round-bottom flask equipped with a reflux condenser, an addition funnel and a 
stirbar.  4-hydroxybenzoic acid (29 g) was added to this solution, and the system was 
heated until reflux. 1,6-dibromohexane (24.6 g) was added dropwise over 2 hours.  The 
reaction was stirred for several hours under reflux.  The product (disodium salt of CPH) 
was dried by vacuum filtration and washed twice with methanol. The product was 
dissolved in distilled water, warmed to 60°C and acidified to pH 2 with H2SO4.  This 
resulted in the free acid of CPP or CPH as a white frothy precipitate.  The product was 
then isolated by vacuum filtration and washed with distilled H2O (200 ml × 2) and 
acetone (200 ml × 2) to remove any trace organics, water, and unreacted 4-
hydroxybenzoic acid.  The final product was then dried overnight in a 60°C oven. 
1,6-bis-carboxyphenoxyhexane dimethacrylate 
1,6-biscarboxyphenoxyhexane dimethacrylate (MCPH) was synthesized from 
CPH and methacryloyl chloride as described by Tarcha (34).  1,6-bis(p-
carboxyphenoxy)hexane (11.3 g) and Et3N (8.08 g) were dissolved in methylene 
chloride (120 mL) and stirred at 0 °C for 45 min. Methacryloyl chloride (7.1g) was added 
dropwise to this solution. Stirring was continued at a reduced temperature for 3.5 h, 
followed by vacuum filtration for removal of precipitated triethyl ammonium chloride. The 
filtrate was washed sequentially with saturated NaHCO3 (200 mL × 2) and distilled H2O 
(200 mL × 2). The solution was dried over anhydrous Na2SO4, and CH2Cl2 was 
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removed in vacuo; a slurry was thereby produced. Then, anhydrous ethyl ether was 
added and removed in vacuo to facilitate the removal of any remaining methylene 
chloride. 
 
Protein formulation 
HRP, FITC-BSA and insulin were used as model proteins. The formulation for 
incorporation into photocrosslinked polyanhydride matrices was based on methods 
described by Baroli (33). In brief, each protein (P) was first pulverized by trituration in a 
Teflon dish with a Teflon-coated spatula. Pulverized protein was then mixed with 
hydroxypropyl-β-cyclodextrin (HPβCD), in a ratio of 1:1 (insulin), 1:50 (FITC-BSA), or 
1:100 (HRP) w/w (P:HPβCD), by geometric dilutions until a homogeneous powder was 
obtained.  Subsequently, this P–HPβCD mixture was granulated with a 5% aqueous 
solution of gelatin B (100 mg of gelatin solution per 1 g of P–HPβCD mixture) to 
produce a slightly wet mass, which was then forced through a 250 µm sieve to yield 
granules. The granulated P–HPβCD mixture was stored at -20°C and analyzed for 
fluorescence (FITC-BSA), antigenicity (insulin) or enzymatic activity (HRP) prior to use.  
To verify the homogeneity of the protein distribution in freshly prepared powders, 
a content uniformity test was used. Prior to granulation, the P–HPβCD mixtures were 
sampled uniformly over their entirety without mixing. Using a sample size of 10 mg 
(n=10 per each formulation), the mixtures were then quantified for enzyme content 
using a Coomassie-based Bradford Assay.  For each set of 10 samples, the mean and 
the standard deviation was calculated. Requirements of the test were considered met if 
the amount of enzyme was within the limits of 85 and 115% of the expected values, and 
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the relative standard deviation (expressed as a percentage) was less than or equal to 
6%. 
 
Sample preparation and photopolymerization 
Photopolymerizations were initiated with a dual initiator strategy, composed of 
camphorquinone (CQ)/4-EDMAB for light-initiated crosslinking, and benzoyl peroxide 
(BPO)/dimethyl toluidine (DMT) for chemically-initiated crosslinking.  Sample 
formulations were prepared by thoroughly mixing the monomers in appropriate 
amounts, followed by adding an appropriate quantity of a BPO/CQ in N-methyl 
pyrrolidone (NMP) followed by 4-EDMAB/DMT in NMP to yield a final quantity of up to 
0.1 wt% for each of CQ, BPO, 4-EDMAB, and DMT in the formulation.  Uniform discs (4 
mm in height and 9 mm in diameter) were prepared in Teflon molds. Samples were 
polymerized with a blue dental lamp (CuringLight XL1500). 
 
 In vitro release studies 
In vitro protein release was assessed in phosphate buffered saline, pH 7.4 at 
37°C to mimic physiological conditions.  Samples were maintained at 60 rpm on an 
orbital shaker throughout degradation studies.  The discs were degraded in 10 ml of 
buffer.  Buffer was replaced at predetermined timepoints for entire duration of the study 
to minimize the effects enzyme deactivation in solution and to maintain sink conditions 
for degradation.   
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HRP activity assay 
 Enzymatic activity of HRP was calculated by quantification of oxidized TMB 
substrate in a peroxide solution using a TMB Substrate Kit.  Serial dilutions of HRP 
release buffer were performed in PBS. 100 µl of each appropriate dilution was added to 
a 96 well plate.  Using a multichannel pipettor, 100 µl of TMB substrate in a peroxidase 
buffer was added and the plate was immediately transferred to a plate reader for 
analysis. The concentration of the oxidized product was measured every 5 minutes for 
30 minutes total at 462 nm on a BioTek II microplate reader.  HRP concentrations in 
release buffer were compared to freshly prepared HRP standards ranging from 0.01 
mU/ml to1 mU/ml.  The linear range for a 30 minute incubation was between 0.01 
mU/ml and 0.25 mU/ml.  The detection limit was 0.01 mU/ml. 
 
Insulin ELISA 
 ELISA was used to quantify insulin release and antigenicity, according to the 
manufacturer’s instructions.  In brief, samples and standards were incubated for two 
hours at 4°C in a 96 well plate that had been preadsorbed with anti-insulin antibody.  
The plate was washed five times, and was then incubated with 100 µl anti-insulin 
enzyme conjugate for 30 minutes at room temperature.  The plate was then washed 
seven times and incubated with 100 µl of TMB substrate for 40 minutes at room 
temperature.  Immediately following the TMB incubation, 100 µl of 2N sulfuric acid was 
added to stop the reaction. The absorbance at 450 nm was measured on a BioTek II 
microplate reader, with a subtraction of the absorbance at 630 nm.  Insulin 
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concentrations were compared to freshly prepared standards ranging from 0.01 to 6.4 
ng/ml.  The detection limit for the assay was 0.01 ng/ml. 
 
Quantification of FITC-BSA fluorescence 
 Concentration of FITC-BSA was quantified by fluorescence at 488 nm on a 
BioTek II microplate reader.  200 µl FITC-BSA containing release buffer was loaded in 
wells of a 96b well plate.  FITC-BSA concentrations were compared to freshly prepared 
standards ranging from 0.01 to 2 µg/ml.  The detection limit for the assay was 0.01 
µg/ml. 
 
Statistical analysis 
 Statistical analysis for comparison of burst release, cumulative release, and rates 
of release was performed using a Student’s t-test with a minimum confidence level of 
0.05 for statistical significance.  All experiments were performed with n = 3-5 and are 
reported as mean ± standard deviation of the mean. 
Results and Discussion 
 
Experimental design 
We have developed a method for protecting proteins from the detrimental effects 
that can occur during incorporation into a photocrosslinked system, such as free radical 
damage (33).  In the current study, HPβCD was selected instead of lactose as the 
excipient, to avoid potential detrimental effects of the reducing sugar.  Cyclodextrins 
have been shown to minimize solution-based and lyophilization-induced aggregation in 
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proteins, as well as to stabilize against degradation and denaturation (36).   The 
resulting uniform powder was then subjected to wet granulation with a 5% aqueous 
bovine gelatin solution.   This excipient and wet granulation strategy served to protect 
the proteins in two ways.  First, the physical barrier of the gelatin granule prevented 
access of the free radicals to the sensitive protein molecules.  Second, the excess of 
HPβCD molecules in comparison to protein minimized the probability of interaction 
between free radicals and the protein. The prepared granules were then incorporated 
into monomer mixtures prior to photocrosslinking.   
Monomer formulations, protein:excipient ratios, and maximum experimental 
lengths are summarized in Table 2.  Protein:excipient ratios were utilized such that the 
lowest level of protein loading that allowed measurable levels during the entire 
experimental length.  This necessitated different levels of loading for the different 
proteins related to release rate and detection sensitivity.  PEGDA incorporation into 
matrices enabled a reduction in water uptake, as shown in previous studies (25). 
Additionally, samples without PEGDA that were loaded with protein granules did not 
maintain structural integrity during degradation (data not shown).  This finding supported 
previous conclusions that PEGDA serves to improve network elasticity via crosslinking.  
MCPH:MSA ratio was a metric for network hydrophobicity, and therefore was a dictator 
of degradation rate (higher ratio was a more hydrophobic network with a slower rate of 
degradation). 
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Table 2: Experimental design – Model proteins, protein:excipient ratios, tested matrix formulations, 
and experimental lengths. 
Protein Protein:Excipient ratio Matrix formulations Length of Experiment 
Insulin 1:1 10% PEGDA 70:30 MCPH:MSA 
10% PEGDA 30:70 MCPH:MSA 
7 days 
7 days 
HRP 1:100 0% PEGDA 70:30 MCPH:MSA 
0% PEGDA 30:70 MCPH:MSA 
5% PEGDA 70:30 MCPH:MSA 
5% PEGDA 30:70 MCPH:MSA 
10% PEGDA 70:30 MCPH:MSA 
10% PEGDA 50:50 MCPH:MSA 
10% PEGDA 30:70 MCPH:MSA 
20% PEGDA 70:30 MCPH:MSA 
20% PEGDA 30:70 MCPH:MSA 
N/A 
N/A 
27 days 
27 days 
120 days 
120 days 
120 days 
27 days 
27 days 
FITC-
BSA 
1:50 10% PEGDA 70:30 MCPH:MSA 
10% PEGDA 50:50 MCPH:MSA 
10% PEGDA 30:70 MCPH:MSA 
27 days 
27 days 
27 days  
 
 
 
Short term release of Insulin, HRP, and FITC-BSA 
 
For evaluation of protein release from photocrosslinked PA networks, three 
model proteins were selected – HRP, FITC-BSA, and insulin.  These proteins possess 
different physiochemical characteristics and can be detected and quantified in solution 
by different assays; these properties are summarized in Table 1.  HRP is a 43 kDa 
protein which is positively charged at a neutral pH (pI = 9.0).  Its structure is 
characterized by four disulfide bonds, seven N-linked carbohydrate residues, one 
pyrrolidone residue, and one heme group.  HRP detection is achieved by enzymatic 
reaction, generally the oxidation of tetramethylbenzidene (TMB) substrate in a peroxide 
buffer.  Detection by enzymatic activity requires maintenance of protein activity during 
and after release.  FITC-BSA is a 67 kDa globular protein with a pI of roughly 4.8 and a 
secondary structure that is roughly 54% α-helix.  Although it has no measurable 
biological activity, labeling of BSA with FITC enables simple, sensitive quantification of 
protein release. Insulin is a polypeptide of 6.7 kDa with a pI of 5.3.  It is composed of 
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two subunits that are linked by two disulfide bonds.  Detection of insulin is carried out by 
ELISA, which verifies maintenance of antigenicity of the epitopes recognized by the 
antibodies.  Selection of these three model proteins with differing characteristics serves 
to verify the robust capabilities for protein delivery in the photocrosslinked PA system.     
 Initially insulin, HRP, and FITC-BSA release were quantified for 7 days (Fig. 2).  
PAs are commonly studied for drug delivery applications as a result of a near zero order 
drug release profile.  In this study, the release profiles deviated from linear release 
profiles.  During the first seven days of degradation and release, FITC-BSA release is 
the most nearly linear (R2 = 0.98) of the three model proteins studied here, followed by 
HRP (R2 = 0.87) and insulin (R2 = 0.83).   Traditional PA matrices used in release 
studies are one-dimensional wafers, which best allow linear release approximation.  
However, in this study, three-dimensional discs were used to more accurately mimic 
potential in vivo applications.  Therefore network dimensions could be one potential 
cause for deviations from a zero order release curve.  Additionally, the detection 
strategy for FITC-BSA (fluorescence) enables the quantification of total protein release.  
In the cases of HRP and insulin, the detection strategies of activity assay or ELISA 
respectively enabled only the quantitation of released protein that has maintained 
activity or antigenicity.  The low levels of protein release in this study prevented 
quantification of total protein release by alternative methodology such as Bradford or 
BCA assay.  If nonlinearities in protein activity or antigenicity occurred, these presented 
themselves in the release profile. 
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Fig. 2 Cumulative release kinetics of insulin 
(A), HRP (B), and FITC-BSA (C) from 
photocrosslinked PA networks (containing 10  
wt% PEGDA) into PBS at 37°C with agitation 
(60 rpm) expressed as normalized protein 
release.  Error bars represent means ± SD for 
n=3-5 
 
 
 
Differences in release between the three proteins can be attributed to several 
different parameters – the physiochemical properties of the protein itself, the nature of 
the detection strategy, or the loading levels of protein within the photocrosslinked 
networks.  Interestingly, the quantity of insulin released was less than 1% of the total 
loaded protein as determined by ELISA, significantly less than HRP or FITC-BSA after 
one week. Similarly, slow release of insulin in comparison to larger molecular weight 
proteins such as BSA and lysozyme has been seen in other sustained release systems 
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(37).  If the mechanism for protein release were dictated purely by erosion of the 
polymer network, it would be expected that the release profile and amount of protein 
release would be unrelated to protein molecular weight.  However, molecular weight 
appeared to play a dominant role.  One suggested mechanism was that sustained 
release occurred via diffusion through matrix channels.  As a result, release was 
dictated by protein properties (solubility and diffusivity) as well as matrix properties 
(porosity and tortuosity).  Small molecular weight macromolecules such as insulin were 
incapable of inducing substantial matrix porosity, therefore hindering release.  
Additionally, insulin can be trapped in micropores throughout the system, while 
macromolecules of larger molecular weight were able to bypass the smallest conduits in 
the network to be more rapidly released into the surrounding buffer.  
An additional mechanism that explains the slow insulin release is that low insulin 
solubility in the aqueous solutions slowed transfer of insulin from the matrix to the 
release buffer.  In our previous study we have shown that contrary to prevailing logic, 
the incorporation of the hydrophilic PEGDA reduced water uptake and swelling in 
comparison with unaugmented matrices, most likely through increased network 
crosslink density (25).    However, even with 10 wt% PEGDA incorporation into the 
system, water uptake of 200% (by mass) has been seen after two weeks of 
degradation.  It was likely that a network of hydrated conduits formed within the 
crosslinked system, facilitating release of the more soluble HRP and FITC-BSA proteins 
with minimal effect on the less soluble insulin. However, this proposed mechanism 
would play a minimal role during short-term release from photocrosslinked PA matrices, 
as acidity produced by the degrading system improves insulin solubility.  An alternative 
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theory is that insulin aggregation into insoluble fibrils occurred within the system.  
Aggregation occurs when hydrophobic residues within the interior of monomeric insulin 
become exposed to the protein surface (38).  Degradation-induced acidity would not be 
sufficient to solublize fibrils, resulting in insulin retention within the network. 
Also contributing to this theory that matrix porosity and protein properties were 
dominant factors in protein release was the observation that MCPH:MSA ratio, the main 
contributor to degradation rate, was not a good predictor of amount of protein release 
during this short-term study.  In both FITC-BSA and insulin release systems, 
formulations with a higher MCPH:MSA  ratio (more slowly degrading) actually provided 
greater protein release during the seven day study.  
 
Long-term release of HRP and FITC-BSA from photocrosslinked PA networks – effect 
of MCPH:MSA ratio 
 
 To evaluate the long-term release behavior and phases of release from 
photocrosslinked PA networks, HRP release was assessed over a 120 day period. 
Release profiles for three MCPH:MSA ratios are displayed in Fig. 3.. In all experiments, 
protein release is expressed a percentage of the theoretical quantity of protein loaded 
per sample.  To quantify observed trends in release rate, release profiles were divided 
into 6 phases, similar to the four phase methodology (over 21 days of release) used to 
describe protein release from an oligo(poly(ethylene glycol) fumarate) hydrogel (39).  
Phase 1 was defined as the burst release after 24 hours of degradation.  Phase 2 was a 
period of rapid release between days 1-3.  Distinct release rates were also noted 
between days 3-6 (Phase 3), days 6-28 (Phase 4) and days 28-60 (Phase 5).  A less 
distinct phase (Phase 6) was seen in the long-term, between days 60 and 120.  In the 
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context of regenerative medicine, phases 1 and 2 constitute priming the environment 
with a bolus of the therapeutic macromolecule.   The remaining long-term release 
phases aid in maintenance of a sustained response, a strategy desired for a single-dose 
vaccine such as tetanus toxoid (40).  
Final cumulative release values are reported for the end of the experiment; 
however significant (>50%) polymer mass remained even at later (120 day) timepoints.  
The burst release cumulative release, and rates of release for each phase can be seen 
in Table 3.  The 70:30 MCPH:MSA network formulation displayed the lowest burst effect 
(3.81±0.62%) after 24 hours of release, while the 50:50 MCPH:MSA and 70:30 
MCPH:MSA displayed similar burst releases (6.22±1.36% and 7.33±0.37% 
respectively).  Phase 2 and 3 release rates were similar for all polymer formulations.  
However, between days 6 and 28 (Phase 4) as well as days 28-60 (Phase 5), 
significantly different rates of HRP release were observed for all three formulations.  
The 30:70 MCPH:MSA formulation had the highest rate of protein release during these 
phases, while the 70:30 MCPH:MSA formulation had the slowest protein release.  The 
slowest overall protein release was seen during the final phase, Phase 6.  As a result of 
a high matrix hydrophobicity, the lowest cumulative release during the study was seen 
in the 70:30 MCPH:MSA formulation.  The 30:70 MCPH:MSA formulation exhibited the 
highest cumulative release. The release from the 70:30 MCPH:MSA formulation was 
significantly lower than the 50:50 and 30:70 formulations throughout the experiment, an 
expected result since this was the most hydrophobic formulation.  
 
 78
Time (d)
0 20 40 60 80 100 120
H
R
P
 R
el
ea
se
 (%
)
0
5
10
15
20
Fig. 3:  Cumulative release kinetics of HRP from photocrosslinked PA networks 
(containing 10 wt% PEGDA) into PBS at 37°C with agitation (60 rpm) expressed 
as normalized active protein release.  Error bars represent means ± standard 
deviation for n=5. 
 
 
Table 3: Burst release, Phase 2-6 release rate and cumulative HRP release from 
photocrosslinked PA networks containing 10 wt% PEGDA. # denotes release that is 
significantly greater than other formulations, ^ denotes release that is significantly less than 
other formulations (p<0.05). 
Formulation Burst 
release 
(%) 
Phase 2 
(day 1-3) 
rate 
(%/day) 
Phase 3 
(day 3-6) 
rate 
(%/day) 
Phase 4 
(day 6-28) 
rate 
(%/day) 
Phase 5 
(day 28-60) 
rate 
(%/day) 
Phase 6 
(day 60-
120) rate 
(%/day) 
Cumulative 
release 
(%) 
30:70 
MCPH:MSA 6.22±1.36 1.94±0.36 0.48±0.09 0.20±0.02# 0.04±0.003# 0.02±0.01 18.41±3.0 
50:50 
MCPH:MSA 7.33±0.37 1.33±0.41^ 0.44±0.07 0.13±0.02 0.03±0.004 0.025±0.01 16.61±1.5 
70:30 
MCPH:MSA 3.81±0.62^ 1.74±0.24 0.46±0.07 0.06±0.02^ 0.02±0.01^ 0.01±0.01^ 11.35±1.4^  
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 These long-term release studies suggested that the mechanism of protein 
release from photocrosslinked PA networks changes during the course of the 
experiment.  The initial burst release most likely occurred as a result of both water 
uptake and the release of protein that is immediately available for dissolution at the 
matrix surface.  In the short-term release period following the initial burst, matrix 
porosity and protein properties presumably play a dominant role as protein release is 
dictated by diffusion.  Finally, in the long-term release phases (Phases 4 - 6), 
dependence on matrix hydrophobicity (MCPH:MSA ratio) was observed.   
 Surprisingly, FITC-BSA release profiles (Fig. 4) and phases of release (Table 4) 
were dramatically different from the release curves for HRP with the same polymer 
network formulations.  For the first 10 days of release, MCPH:MSA ratio appeared to 
play no significant role in dictating rate of protein release. Interestingly, the Phase 2 
(day 1-3) rates were statistically different for all formulations; although, the highest 
MCPH:MSA ratio formulation (most hydrophobic and most slowly degrading) had the 
greatest rate of FITC-BSA release during this time.  The release behavior during the 
initial phases (burst release and Phases 2-3) suggests that matrix degradation was not 
a predominant factor during the short term release.  During this time, a gradual wetting 
of the matrix may have led to induction of porosity and diffusion of the protein into the 
release buffer. However, in Phase 4 (days 6-27), significantly different release rates 
were again seen in all formulations.  In this phase, the MCPH:MSA ratio was a good 
predictor of the rate of release.  More rapid FITC-BSA release was seen in the more 
rapidly degrading 30:70 MCPH:MSA formulation.  Correspondingly, the lowest rate of 
FITC-BSA release was seen in the slowest degrading 70:30 MCPH:MSA formulation 
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during Phase 4.  The reliance on matrix degradation during Phase 4 was a common 
factor in release of both HRP and FITC-BSA, despite differences in the overall rate of 
release and release profiles between the two proteins. 
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Fig. 4: Cumulative release kinetics of FITC-BSA from photocrosslinked PA 
networks (containing 10 wt% PEGDA) into PBS at 37°C with agitation (60 rpm) 
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Table 4: Burst release, Phase 2-5 release rate and cumulative FITC-BSA release from 
photocrosslinked PA networks containing 10 wt% PEGDA. . # denotes release that is 
significantly greater than other formulations, ^ denotes release that is significantly less 
than other formulations (p<0.05). 
Formulation Burst 
release (%) 
Phase 2 
(day 1-3) 
rate 
(%/day) 
Phase 3 
(day 3-6) 
rate 
(%/day) 
Phase 4 
(day 6-27) 
rate 
(%/day) 
Phase 5 
(day 27-41) 
rate 
(%/day) 
Cumulative 
release (%) 
30:70 MCPH:MSA 0.46±0.25^ 1.10±0.32^ 3.04±0.51 2.24±0.09# 0.42±0.22 64.74±5.89#
50:50 MCPH:MSA 1.94±0.94 1.84±0.74 2.70±0.81 1.06±0.20 0.33±0.06 40.54±5.89 
70:30 MCPH:MSA 1.99±0.41 3.09±0.35# 2.57±0.23 0.61±0.11^ 0.31±0.37 33.36±8.14 
 
 
 Long-term release of HRP – effect of PEGDA concentration 
Previous studies in our laboratory have shown that incorporation of PEGDA into 
photocrosslinked matrices minimizes water uptake and buffer acidity during in vitro 
degradation. Although we have determined that inclusion of PEGDA is beneficial for 
performance of the material in in vitro degradation, some dose dependence was seen 
with different percentages of PEGDA in photocrosslinked PA formulations. To assess 
the effect of PEGDA loading on protein release, HRP-containing formulations described 
in Table 2 were evaluated.  Interestingly, samples containing 0 wt% PEGDA did not 
remain intact for more than 4 days of in vitro degradation (data not shown). This result 
provides conclusive evidence that PEGDA is a critical component of photocrosslinked 
PA systems for protein release.  In earlier studies, the proposed mechanism for 
reduction in water uptake by PEGDA (despite the molecule’s hydrophilicity) was the 
introduction of a more densely crosslinked network and a reduction in the concentration 
of unreacted monomer.  A system that was not augmented by PEGDA most likely 
lacked sufficient crosslinking density and elasticity to maintain structural integrity with 
the inclusion of protein granules.  
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Formulations containing 5% or 20% PEGDA displayed a similarly shaped release 
profile (Fig 5.)  as previously described for the 10% PEGDA formulations (Fig. 3).  Burst 
releases and Phase 1 release rates for the 20% PEGDA formulations were higher than 
the 5% PEGDA formulations (Table 5).  As expected from earlier experiments, the 
MCPH:MSA ratio did not play a significant role in protein release during these phases.  
However, during Phases 3 and 4, the MCPH:MSA ratio was a better predictor of release 
rate, with the 30:70 MCPH:MSA ratio yielding more rapid release.  Final cumulative 
HRP release was significantly greater for the 20% PEGDA loading than for the 5% 
PEGDA loading within a given MCPH:MSA ratio.  Final cumulative HRP release was 
greater for the 30:70 MCPH:MSA ratio within a given PEGDA loading.  These data 
suggested that matrix hydrophilicity played a role in increasing protein release since 
both high PEGDA concentrations and low MCPH:MSA ratios yielded greater protein 
release, thus presenting a novel mechanism for controlling macromolecular release 
from hydrophobic matrices. FITC-BSA release was quantified from similar formulations; 
however no difference in release rate was seen with alternative PEGDA loading (5 or 20 
wt%) (data not shown).  This finding suggested that physical properties of the protein 
may alter the effect of PEGDA on release profiles.   
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Fig. 5: Cumulative release kinetics of HRP from photocrosslinked PA networks 
(containing 5 or 20 wt% PEGDA) into PBS at 37°C with agitation (60 rpm) 
expressed as normalized active protein release.  Error bars represent means ± 
SE for n=4. 
 
 
 
Table 5: Burst release, Phase 2-4 release rate and cumulative HRP release 
rom photocrosslinked PA networks containing 5 or 20 wt% PEGDA. f 
Formulation Burst 
release (%) 
Phase 2 
(day 1-3) 
rate 
(%/day) 
Phase 3 
(day 3-6) 
rate 
(%/day) 
Phase 4 
(day 6-27) 
rate 
(%/day) 
Cumulative 
release (%) 
5% PEGDA  
30:70 MCPH:MSA 7.30±2.17 5.67±0.86 3.93±0.69 0.50±0.08 41.73±3.89 
5% PEGDA  
70:30 MCPH:MSA 8.82±0.71 4.01±0.51 0.81±0.08 0.19±0.02 23.30±1.54 
20% PEGDA  
30:70 MCPH:MSA 16.36±1.85 13.38±0.94 2.20±0.06 0.38±0.04 57.57±2.52 
20% PEGDA  
70:30 MCPH:MSA 11.82±0.64 10.36±1.84 2.13±0.46 0.25±0.04 44.96±6.02 
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Conclusions 
This study is the first to evaluate protein release from photocrosslinked PA 
networks.  More importantly, sustained long-term release (> 4 months) of 
macromolecules in their active form from photocrosslinked PA networks has been 
demonstrated.  Three model proteins, that differ in their physicochemical and detection 
modalities have been incorporated into the matrices and released in vitro.   By varying 
the network hydrophobicity (MCPH:MSA ratio or PEGDA content) the release profiles 
were tuned to achieve varying rates of protein release from the matrices, although these 
effects were seen primarily in the later phases of release.  This observation constitutes 
a novel mechanism for controlling macromolecular release from hydrophobic matrices. 
Interestingly, especially during the early phases of protein release, the physicochemical 
properties of individual proteins are a dominant factor in determining protein release.  
These findings validate the photocrosslinked PA system as an injectable vehicle for 
macromolecule delivery with broad clinical applications.  
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Abstract 
Injectable delivery systems are attractive as vehicles for localized delivery of 
therapeutics especially in the context of regenerative medicine.  In this study, 
photocrosslinked polyanhydride (PA) networks were modified by incorporation of 
microparticles to enhance and modulate long-term delivery of macromolecules.  The in 
vitro release of two model proteins (horseradish peroxidase (HRP) and bovine serum 
albumin labeled with fluorescein isothiocyanate (FITC-BSA)) were evaluated from 
photocrosslinked anhydride networks composed of sebacic acid dimethacrylate (MSA), 
1,6-bis-carboxyphenoxyhexane dimethacrylate (MCPH), poly(ethylene glycol) diacrylate 
(PEGDA), and calcium carbonate (CaCO3), supplemented with gelatin microparticles or 
sodium chloride (NaCl) crystals.  The proteins were formulated into granules first by 
dilution with a cyclodextrin excipient through tituration, followed by gelatin-based wet-
granulation prior to incorporation into the networks.  Protein release was quantified over 
predetermined time periods by activity assay (HRP) or fluorescence (FITC-BSA).  
Protein release profiles and rates of protein release were successfully modulated by 
incorporation of microparticles into photocrosslinked PA networks, presumably by 
enabling aqueous channels through the matrix.  By loading the protein in the gelatin 
microparticles, additional control over protein release was achieved.  Furthermore, a 
dual release system has been demonstrated by incorporation of protein in both the PA 
matrix and the gelatin microparticles.  These results suggest that microparticle 
incorporation into photocrosslinked PA system may be a useful strategy to modulate 
protein release in injectable delivery systems for the long-term delivery of 
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macromolecules.  These gelatin microparticle-photocrosslinked composites present an 
interesting class of materials for bone regeneration applications. 
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Introduction 
In the recent past, our laboratory efforts have focused on the exploration of the 
photocrosslinked polyanhydride (PA) system as a scaffold for hard tissue regeneration 
and drug delivery. This system is based on anhydride monomers with reactive 
methacrylate functionalities and has been developed for use in orthopedic tissue repair 
and regeneration (1). Upon exposure to light radiation, this system can be rapidly 
crosslinked in situ into a high strength degradable network.  This system has several 
advantages over traditional PLGA systems for drug delivery. First, as a result of the 
anhydride linkages, PA based systems are capable of undergoing surface erosion and 
achieving predictable near-zero order drug release.  Additionally, the capability of in situ 
formation is of particular importance in TE applications in which physical conformation 
of the device to an implant site is an important prerequisite for optimal tissue healing.   
We have shown that a traditional photocrosslinked PA system composed of 
MCPH and MSA can be easily modified with additives such as CaCO3 and PEGDA to 
modulate degradation properties such as mass loss, water uptake, pH and mechanical 
strength while providing no adverse effects on the crosslinking capabilities of the system 
(2).  Additionally, we have demonstrated that this system possesses a robust capability 
for long-term delivery of macromolecules (3).  We have implemented a protein 
stabilization strategy previously developed in our laboratory to protect proteins from free 
radicals during polymerization (4), with some minor modifications to stabilize and 
disperse the protein in the PA system developed for the spinal fusion application. Using 
these strategies, we have demonstrated that the photocrosslinked PA system can serve 
as an injectable vehicle for the long-term delivery of active proteins.  Although most 
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studies of the photocrosslinked PA system have focused on orthopedic applications, a 
more general application would involve intra-muscular and sub-dermal injectable 
systems capable of long-term delivery of macromolecules. 
In our previous work, we were able to achieve long-term (over four months) 
release of enzymatically active protein (HRP), although relatively low levels of protein 
release were attained.  The release rate and profile were modestly modulated by 
altering matrix hydrophobicity (MCPH:MSA ratio or PEGDA content).  Significant 
modulation of protein release rates and profiles is difficult in this photocrosslinked 
system outside of altering matrix hydrophobicity.  Although reactive and nonreactive 
additives can be incorporated with ease, an upper limit exists after which crosslinking 
and/or structural integrity of the system is impaired.   
 One proposed driving force for protein release (in addition to degradation) is 
protein diffusion through aqueous channels in the wetted network.  Maximization of the 
channel volume within the matrix by incorporation of porogens would be one 
mechanism for increasing release. One possible methodology for induction of 
microscale channels is the incorporation of microparticles or salt crystals within the 
crosslinked matrix (5). In the field of TE, microparticles alone suffer limitations, since 
they do not provide a substrate for cellular or tissue ingrowth.  However diverse uses 
have been identified for incorporation of microparticles into TE scaffolds.  Initially, 
leachable porogens such as microparticles of gelatin or NaCl have been used to 
generate porosity in scaffolds by solvent casting or particulate leaching. More recently, 
drug or protein-loaded microparticles have been incorporated into TE scaffolds (such as 
polypropylene fumarate (5) or oligo(poly(ethylene glycol) fumarate) (6)) to form 
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composites with the capability of delivering bioactive molecules that aid in tissue 
regeneration.  For these drug delivery applications, biodegradable microparticles 
composed of gelatin (7), co-polymers of lactic acid and glycolic acid (PLGA) (5), or 
polyanhydrides (PA) (8) have garnered much interest.   
In the current study, two model proteins (HRP and FITC-BSA) were selected for 
release from porous photocrosslinked PA networks.  The current strategies employed 
include both particulate leaching of NaCl and gelatin microparticles as well as release of 
protein from composites composed of protein loaded gelatin microparticles within 
photocrosslinked PA networks (see Fig. 1).  This study is the first to evaluate the 
incorporation of porogens in the photocrosslinked PA system.  In addition, it is the first 
to employ the particulate leaching strategy as a primary means of facilitating protein 
release. The overall objective of this study was therefore to demonstrate the ease of 
modulation of this system for improving delivery of peptides and proteins.  Specifically, 
we aim to answer the following questions: (1) To what extent can the delivery of 
macromolecules be controlled by incorporation of porogens (NaCl and gelatin 
microparticles) within the matrix? (2) Can the protein carrier affect protein release? and 
(3) Does the physiochemical nature of the macromolecule affect release?  By answering 
these questions, we have expanded on our previous studies to demonstrate versatility 
in release profiles from the photocrosslinked PA system for the long-term delivery of 
active macromolecules. 
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Sebacic acid  dimethacrylate (MSA) Polyethylene glycol diacrylate (PEGDA) MW 700
Photoinitiator/
UV/Visible Light
n = 6, 1,6-biscarboxyphenoxyhexane
dimethacrylate (MCPH)
CaCO3
Protein Formulation – Protein + 
Sugar in Gelatin granules
Gelatin 
microparticles
Fig. 1:  Schematic of photocrosslinking.  Anhydride monomers (MSA, MCPH), 
PEGDA, CaCO3 and protein granules were mixed to form a paste.  Mixtures were 
photocrosslinked after addition of photoinitiators and exposure to visible light.   
 
 
 
Experimental 
 
 
Materials 
 Methacrylic acid, sebacoyl chloride, triethylamine, methylene chloride, sodium 
bicarbonate, sodium sulfate, 4-hydroxybenzoic acid, 1,6-dibromohexane, methacryloyl 
chloride, poly(ethylene gycol) diacrylate (PEGDA), camphorquinone, ethyl 4-
(dimethylamino)benzoate (4-EDMAB), benzoyl peroxide, dimethyl toluidine, n-methyl 
pyrrolidone, bovine serum albumin fluorescein isothiocyanate conjugate (FITC-BSA), 
calcium carbonate, bovine gelatin B, and glutaraldehyde were obtained from Sigma-
Aldrich. Horseradish peroxidase, TMB substrate kits and Coomassie-based Bradford 
assay kits were purchased from Pierce.  All materials were used as received. 
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Monomer synthesis 
Sebacic acid dimethacrylate 
Sebacic acid dimethacrylate (MSA) was synthesized from methacrylic acid and 
sebacoyl chloride as described by Tarcha (9).  Methacrylic acid (9 g) and triethylamine 
(Et3N) (11.63 g) were dissolved in methylene chloride (150 ml), and the mixture was 
stirred at 0°C for 30 min. Sebacoyl chloride (12.5 g) was added dropwise to the solution. 
Stirring was continued for 1 h at a reduced temperature, followed by vacuum filtration 
for removal of the precipitated triethyl ammonium chloride. The filtrate was diluted with 
an additional 100 mL of methylene chloride and cooled to 0°C. The solution was 
washed sequentially with saturated NaHCO3 (250mL × 2) and distilled H2O (250mL × 2) 
and dried over Na2SO4. Methylene chloride was then removed in vacuo at 0°C.  
1,6-bis-carboxyphenoxyhexane 
 1,6-bis-carboxyphenoxyhexane (CPH) was synthesized from 4-hydroxybenzoic 
acid and 1,6-dibromohexane based on the synthesis of 1,3-bis-carboxyphenoxypropane 
described by Conix (10).  NaOH (20 g) was dissolved in distilled water (100 ml) in a 500 
ml round-bottom flask equipped with a reflux condenser, an addition funnel and a 
stirbar.  4-hydroxybenzoic acid (29 g) was added to this solution, and the system was 
heated until reflux. 1,6-dibromohexane (24.6 g) was added dropwise over 2 hours.  The 
reaction was stirred for several hours under reflux.  The product (disodium salt of CPH) 
was dried by vacuum filtration and washed twice with methanol. The product was 
dissolved in distilled water, warmed to 60°C and acidified to pH 2 with H2SO4.  This 
resulted in the free acid of CPP or CPH as a white frothy precipitate.  The product was 
then isolated by vacuum filtration and washed with distilled H2O (200 ml × 2) and 
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acetone (200 ml × 2) to remove any trace organics, water, and unreacted 4-
hydroxybenzoic acid.  The final product was then dried overnight in a 60°C oven. 
1,6-bis-carboxyphenoxyhexane dimethacrylate 
1,6-biscarboxyphenoxyhexane dimethacrylate (MCPH) was synthesized from 
CPH and methacryloyl chloride as described by Tarcha (9).  1,6-bis(p-
carboxyphenoxy)hexane (11.3 g) and Et3N (8.08 g) were dissolved in methylene 
chloride (120 mL) and stirred at 0 °C for 45 min. Methacryloyl chloride (7.1g) was added 
dropwise to this solution. Stirring was continued at a reduced temperature for 3.5 h, 
followed by vacuum filtration for removal of precipitated triethyl ammonium chloride. The 
filtrate was washed sequentially with saturated NaHCO3 (200 mL × 2) and distilled H2O 
(200 mL × 2). The solution was dried over anhydrous Na2SO4, and CH2Cl2 was 
removed in vacuo; a slurry was thereby produced. Then, anhydrous ethyl ether was 
added and removed in vacuo to facilitate the removal of any remaining methylene 
chloride. 
 
Protein formulation 
HRP and FITC-BSA were used as model proteins. The formulation for 
incorporation into photocrosslinked polyanhydride matrices was based on methods 
described by Baroli (4). In brief, each protein (P) was first pulverized by trituration in a 
Teflon dish with a Teflon-coated spatula. Pulverized protein was then mixed with 
hydroxypropyl-β-cyclodextrin (HPβCD), in a ratio 1:50 (FITC-BSA) or 1:100 (HRP) w/w 
(P:HPβCD), by geometric dilutions until a homogeneous powder was obtained.  
Subsequently, this P–HPβCD mixture was granulated with a 5% aqueous solution of 
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gelatin B (100 mg of gelatin solution per 1 g of P–HPβCD mixture) to produce a slightly 
wet mass, which was then forced through a 250 µm sieve to yield granules. The 
granulated P–HPβCD mixture was stored at -20°C and analyzed for fluorescence 
(FITC-BSA) or enzymatic activity (HRP) prior to use.  
To verify the homogeneity of the protein distribution in freshly prepared powders, 
a content uniformity test was used. Prior to granulation, the P–HPβCD mixtures were 
sampled uniformly over their entirety without mixing. Using a sample size of 10 mg 
(n=10 per each formulation), the mixtures were then quantified for enzyme content 
using a Coomassie-based Bradford Assay.  For each set of 10 samples, the mean and 
the standard deviation was calculated. Requirements of the test were considered met if 
the amount of enzyme was within the limits of 85 and 115% of the expected values, and 
the relative standard deviation (expressed as a percentage) was less than or equal to 
6%. 
 
Preparation of gelatin microparticles 
 Gelatin microparticles were fabricated as described by Holland (6).  Briefly, 5 g of 
basic gelatin was dissolved in 45 ml of deionized water by heating to 60°C under 
constant stirring.  The aqueous gelatin solution was added dropwise via a syringe and 
21-G needle to 250 ml of olive oil while maintaining a stirring rate of 500 rpm.  Stirring 
was maintained while the emulsion temperature was decreased to 15°C to induce 
gelation.  After 30 minutes, 100 ml of chilled acetone were added.  The microparticles 
were removed by vacuum filtration and were washed 4 times with acetone to remove 
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residual olive oil.  Microparticles were sized by passing through sieves of sizes ranging 
from 500 µm to 106 µm. 
 
Crosslinking of gelatin microparticles 
 Gelatin microparticles were crosslinked by stirring in a 0.1% solution of Tween 80 
containing 0.5% glutaraldehyde for 12 h at 15°C.  Crosslinked microparticles were 
collected by vacuum filtration.  The microparticles were washed in deionized water and 
then incubated in a 25 mM glycine solution for 1 h to block any unreacted 
gluteraldehyde.  The microparticles were collected by vacuum, washed in deionized 
water, and vacuum-dried overnight.  Crosslinked microparticles were then sized by 
passing through a gradient of sieves. 
 
Protein loading of gelatin microparticles 
 Solutions of protein in phosphate buffered saline were prepared for loading of the 
crosslinked gelatin microparticles.  Microparticle loading was achieved by incubating 5 
µl of protein solution (2 mg/ml, HRP or FITC-BSA) per mg of gelatin microparticles.  
This solution volume was significantly below the theoretical equilibrium swelling volume 
of the microparticles, ensuring complete protein adsorption by the particles.  The 
microparticle-protein mixture was vortexed completely and incubated overnight at 4°C to 
allow adsorption to occur. 
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In vitro protein release from gelatin microparticles 
 HRP and FITC-BSA release from crosslinked gelatin microparticles was 
assessed in PBS.  Loaded microparticle were weighed and incubated with 1 ml of PBS.  
All specimens were incubated at 37°C with shaking (60 rpm).  At predetermined 
timepoints, the specimens were pelleted by centrifugation. The release buffer was 
removed and replaced with fresh PBS.  The presence of protein in the release buffer 
was quantified by correlation with a standard curve (see assays for HRP and FITC-BSA 
below).  Cumulative protein release was quantified by calculating the cumulative protein 
release and normalizing to the total loaded protein in each specimen. 
 
Sample preparation and photopolymerization 
Photopolymerizations were initiated with a dual initiator strategy, composed of 
camphorquinone (CQ)/4-EDMAB for light-initiated crosslinking, and benzoyl peroxide 
(BPO)/dimethyl toluidine (DMT) for chemically-initiated crosslinking. as previously developed 
and described (2).  Sample formulations were prepared by thoroughly mixing the monomers in 
appropriate amounts, followed by adding an appropriate quantity of a BPO/CQ in N-methyl 
pyrrolidone (NMP) followed by 4-EDMAB/DMT in NMP to yield a final quantity of up to 0.1 wt% 
for each of CQ, BPO, 4-EDMAB, and DMT in the formulation.  Uniform discs (4 mm in height 
and 9 mm in diameter) were prepared in Teflon molds. Samples were polymerized with a blue 
dental lamp (CuringLight XL1500). 
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In vitro release studies 
In vitro protein release was assessed in phosphate buffered saline, pH 7.4 at 
37°C to mimic physiological conditions.  Samples were maintained at 60 rpm on an 
orbital shaker throughout degradation studies.  The discs were degraded in 10 ml of 
buffer.  Buffer was replaced at predetermined timepoints for entire duration of the study 
to minimize the effects enzyme deactivation in solution and to maintain sink conditions 
for degradation.   
 
HRP activity assay 
 Enzymatic activity of HRP was calculated by quantification of oxidized TMB 
substrate in a peroxide solution using a TMB Substrate Kit.  Serial dilutions of HRP 
release buffer were performed in PBS. 100 µl of each appropriate dilution was added to 
a 96 well plate.  Using a multichannel pipettor, 100 µl of TMB substrate in a peroxidase 
buffer was added and the plate was immediately transferred to a plate reader for 
analysis. The concentration of the oxidized product was measured every 5 minutes for 
30 minutes total at 462 nm on a BioTek II microplate reader.  HRP concentrations in 
release buffer were compared to freshly prepared HRP standards ranging from 0.01 
mU/ml to1 mU/ml.  The linear range for a 30 minute incubation was between 0.01 
mU/ml and 0.25 mU/ml.  The detection limit was 0.01 mU/ml. 
 
Quantification of FITC-BSA fluorescence 
 Concentration of FITC-BSA was quantified by fluorescence at 488 nm on a 
BioTek II microplate reader.  200 µl FITC-BSA containing release buffer was loaded in 
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wells of a 96b well plate.  FITC-BSA concentrations were compared to freshly prepared 
standards ranging from 0.01 to 2 µg/ml.  The detection limit for the assay was 0.01 
µg/ml. 
 
Statistical analysis 
 Statistical analysis for comparison of burst release, cumulative release, and rates 
of release was performed using a Student’s t-test with a minimum confidence level of 
0.05 for statistical significance.  All experiments were performed with n = 3-5 and are 
reported as mean ± standard deviation of the mean. 
 
Results 
 
 
HRP release from photocrosslinked PA matrices with NaCl-or gelatin microparticle-
induced porosity 
 
 Although previous experimentation in our laboratory demonstrated capability of 
delivering active proteins over a long timeframe at a tunable rate, the cumulative HRP 
release was less than 20% of total loaded HRP after 35 days. We therefore 
hypothesized that the introduction water soluble porogens such as NaCl or gelatin 
microparticles might accelerate the release of HRP (see formulations in Table 1a).  The 
most hydrophobic network (MCPH:MSA) was selected, as it resulted in the slowest 
protein release in unmodified systems. Introduction of 25 w/w% of 250 µm gelatin 
microspheres into the system resulted in the release of 56% of loaded HRP over a 5-
week period which represents a five-fold increase over the 10% release seen in the 
unmodified system.  A significant increase in protein release was seen both during the 
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24 hour burst release (p=0.001) as well as during the long term release phase (days 7-
35, p=0.005) in the gelatin microparticle supplemented system.  However, when NaCl 
particles (<106 µm) were incorporated into networks as a porogen, no difference in 
release rate occurred in comparison with the unmodified, nonporous matrix. This is an 
important result as it suggests that the leaching of dissolved gelatin leaves an aqueous 
path, whereas the complete ionic dissolution of NaCl does not result in new aqueous 
pathways or macroporosity for protein diffusion.  Fig. 2 shows the release profiles over 
35 days for these three formulations. In addition, Table 2 compares the 24 hour burst 
effect release, the cumulative release after 48 hours, the long-term release rate 
(between days 7 and 35), and the total cumulative release rate for the unmodified, 
nonporous network, and for the network containing 250 µm gelatin microparticles.  
There is a statistically significant difference for all calculated parameters in this table.  
There is only a difference in burst release between the unmodified, nonporous network 
and the network containing <106 µm NaCl crystals. This modification to our HRP 
release studies shows that we can modulate the rate of release of active protein from 
our crosslinked anhydride system. Further enhancement in protein release can be 
achieved by varying the size, volume fraction or type of porogen.  
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Fig. 2: Cumulative release kinetics of HRP from photocrosslinked 
anhydride networks containing gelatin microparticles (A) or NaCl 
particles (B) into PBS at 37°C with agitation (60 rpm). Error bars 
represent mean±S.E. for n=2-4.   
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 Table 1: Experimental design for evaluation of microparticle leaching for 
modulation of protein release 
 MCPH:MSA 
ratio 
Granulated 
protein 
Microparticle 
loading 
Microparticle 
size 
Microparticle 
type 
a. 70:30 HRP 25 w/w% < 106 µm NaCl 
 70:30 HRP 25 w/w% 250 µm Gelatin B 
b. 70:30 HRP 75 v/v% 180-250 µm Gelatin B 
 70:30 HRP 75 v/v% 250-300 µm Gelatin B 
c. 70:30 HRP 33 v/v% 106-180 µm Gelatin B 
 70:30 HRP 55 v/v% 180-250 µm Gelatin B 
 30:70 HRP 33 v/v% 180-250 µm Gelatin B 
 30:70 HRP 55 v/v% 106-180 µm Gelatin B  
 
 
 
Table 2: Release rates of HRP from crosslinked anhydride networks 
Formulation 24 h 
Burst (%) 
Cumulative 
release after 
48 h 
(%) 
Long term 
release (d7 – 
d35)  
(%/d) 
Cumulative 
release (%) 
70:30 
MCPH:MSA 
3.81±0.7
0 
5.61±0.78 0.05±0.02 10.33±0.89 
70:30 
MCPH:MSA + 
gelatin 
µparticles 
15.22±2.
54 
41.72±17.29 0.518±0.16 56.71±18.61 
 
 
 
HRP release from photocrosslinked PA matrices with gelatin-microparticle-induced 
porosity: Effect of loading and particle size 
 
 Since gelatin microparticles were better modulators of protein release than NaCl 
crystals, preliminary studies were pursued with gelatin microparticles alone.  Initially, 
gelatin microparticles of two size ranges (180-250 µm and 250-300 µm) were 
incorporated into photocrosslinked PA networks at a loading of 75 v/v%, the maximal 
loading allowable (formulations described in Table 1b).  Large microparticles were 
selected to maximize the effect in these proof-of-concept studies.  HRP release profiles 
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from these networks can be seen in Fig. 3.  During the first eight days of degradation 
and release, the release profiles were identical, regardless of microparticle size.  After 
day eight, the rate of HRP release from samples containing 180-250 µm microparticles 
was 0.48±0.11% per day, while the rate of HRP release from samples containing 250-
300 µm microparticles was 1.22±0.06% per day (p<0.05).  Since larger (250-300 µm) 
were often the result of the aggregation of smaller particles, additional studies utilized 
smaller, more uniform microparticles. 
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Fig. 3: Cumulative release kinetics of HRP from photocrosslinked 
anhydride networks containing gelatin microparticles into PBS at 37°C 
with agitation (60 rpm). (A) The cumulative normalized mass released 
from samples containing 75 v/v% gelatin microparticles, error bars 
represent mean±S.E. for n=2-4.   
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 To evaluate the effect of gelatin microparticle size and loading on protein release, 
gelatin microparticles of two size ranges (106-180 µm and 180-250 µm) were utilized at 
loadings of 33 or 55 v/v%.  Additionally, two MCPH:MSA ratios – 30:70 and 70:30 were 
evaluated.  These formulations are described in Table 1c. Interestingly, the release 
profile was independent of microparticle loading and MCPH:MSA ratio (Fig. 4). As 
expected based on percolation theory, gelatin microparticle size was the dominant 
factor in dictating HRP release.  The larger microparticles (180-250 µm) yielded greater 
cumulative protein release than the smaller microparticles (106-180 µm) (p<0.05) 
regardless of MCPH:MSA ratio or microparticle loading percentage.  This long-term 
release profile was primarily dominated by the release of HRP over the first 48 hours. 
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Fig. 4: Cumulative release kinetics of HRP from photocrosslinked 
anhydride networks containing gelatin microparticles into PBS at 37°C 
with agitation (60 rpm). The cumulative normalized mass released from 
samples containing 106-180 µm or 180-250 µm gelatin microparticles, 
error bars represent mean±S.D. for n=4.   
 
 
 
Gelatin microparticles as protein delivery vehicles  
 Gelatin microparticles were also studied as a vehicle for protein delivery. 
Microparticles were loaded with a 2 mg/ml solution of FITC-BSA or HRP in PBS by 
swelling.   Ten mg samples of loaded microparticles were then incubated in PBS 
release buffer.  Combinations of protein type and microparticle size are described in 
Table 3a. The buffer was removed at predetermined timepoints and protein release was 
quantified (Fig. 5).  Microparticles (106-180 µm) loaded with FITC-BSA exhibited a 24 
hour burst release of 59.98±0.79% of loaded protein, while those loaded with HRP 
exhibited a smaller burst release than that of FITC-BSA (14.01±2.13%).  Larger 
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microparticles (180-250 µm) loaded with HRP exhibited the smallest burst release 
(11.43±1.15%).  Since the 180-250 µm particles were less uniform than smaller 
microparticles (data not shown), these were not used to evaluate FITC-BSA release nor 
were they utilized in future studies.  Final cumulative release was the greatest for FITC-
BSA (93.49±2.2% of loaded protein after 18 days).  In contrast, 81.64±0.07% of loaded 
HRP was released from the 106-180 µm microparticles and 60.57±0.01% of loaded 
HRP was released from 180-250 µm microparticles.  As expected, the total cumulative 
release of HRP was greater from the smaller microparticles, presumably a result of the 
increased surface area to volume ratio over the larger microparticles.
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Fig. 5: Crosslinked gelatin microparticles were loaded with a solution of 
FITC-BSA or HRP; protein was released in 1 ml of PBS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Experimental design for evaluation of protein release from loaded 
gelatin microparticles and from photocrosslinked PA networks 
 Matrix Granulated 
protein 
Microparticle 
loading 
Microparticle 
size 
Protein loaded 
in 
microparticles 
a. N/A N/A N/A 106-180 µm FITC-BSA 
 N/A N/A N/A 106-180 µm HRP 
 N/A N/A N/A 180-250 µm HRP 
b. 70:30 
MCPH:MSA 
HRP 10 w/w% 106-180 µm FITC-BSA 
 70:30 
MCPH:MSA 
FITC-BSA 10 w/w% 106-180 µm HRP 
 
 
 
 
 
 
 
 111
Dual release system for HRP and FITC-BSA from photocrosslinked PA matrix-gelatin 
microparticle composites 
 
 Composites of photocrosslinked PA networks and gelatin microparticles were 
fabricated to evaluate co-release of FITC-BSA and HRP.  One set of composites was 
created which contained FITC-BSA in the traditional wet granulated protein and 
cyclodextrin formulation and HRP-loaded gelatin microparticles.  Another set of 
composites contained HRP in the traditional wet granulated protein and cyclodextrin 
formulation and FITC-BSA-loaded gelatin microparticles.  A schematic for protein and 
microparticle loading is shown in Fig. 6.  Release profiles were dependent on both the 
phase of protein loading (within gelatin microparticles or within the granulated 
formulation) and the type of protein (formulations described in Table 3b).  When HRP 
was incorporated into composites in the granulated formulation with FITC-BSA loaded 
gelatin microparticles (Fig. 7), there was a burst release of 9.66±2.45% of loaded HRP 
after 24 hours.  After 18 days, the cumulative release of HRP was 11.20±0.002% of the 
theoretical loading.  Interestingly, only 0.02+0.008% of FITC-BSA from the composites 
was released after 18 days, with no detectable burst release.  In contrast, when FITC-
BSA was incorporated into composites in the granulated formulation with HRP loaded 
gelatin microparticles (Fig. 8), there was a burst release of 5.73±0.87% of loaded FITC-
BSA after 24 hours.  After 18 days, the cumulative release of FITC-BSA was 
82.7±0.47% of the theoretical loading.  HRP release from gelatin microparticles within 
the composite yielded a burst release of 30.32±0.19%.  Final cumulative release of HRP 
after 18 days was 34.00±0.20% of the theoretical loading. 
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FITC-BSA in granulated protein formulation
HRP loaded into gelatin microparticles
HRP in granulated protein formulation
FITC-BSA loaded into gelatin microparticles
Photocrosslinked PA network
Gelatin microparticle
HRP
FITC-BSA
Fig. 6: Schematic for dual release strategy.  Specimen contained HRP in the 
wet-granulated formulation and FITC-BSA-loaded gelatin microparticles or FITC-
BSA in the wet-granulated formulation and HRP-loaded gelatin microparticles. 
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Fig. 7: Cumulative release kinetics of HRP and FITC-BSA from photocrosslinked 
anhydride networks containing gelatin microparticles into PBS at 37°C with 
agitation (60 rpm). Samples contained traditionally formulated HRP (sugar+ 
protein+ granulation) (10 wt%) and FITC-BSA loaded gelatin microparticles (10 
wt%).The cumulative normalized mass released from samples is shown, error 
bars represent mean±S.D. for n=2-4.  
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Fig. 8: Cumulative release kinetics of HRP and FITC-BSA from photocrosslinked 
anhydride networks containing gelatin microparticles into PBS at 37°C with 
agitation (60 rpm). Samples contained traditionally formulated FITC-BSA (sugar+ 
protein+ granulation) (10 wt%) and HRP loaded gelatin microparticles (10 
wt%).The cumulative normalized mass released from samples is shown, error 
bars represent mean±S.D. for n=2-4. 
 
 
 
Discussion 
 
Our laboratory has been the first to evaluate protein release from 
photocrosslinked PA networks (3).  This delivery system was initially selected as a 
result of numerous properties including the potential for predictable near-zero order 
release profiles, the capability of formation in situ by virtue of photocrosslinking, and the 
relative ease of system modification. In our initial study, sustained long-term release (> 
4 months) of macromolecules in their active form from photocrosslinked PA networks 
was demonstrated.  Additionally, the release profiles of the evaluated macromolecules 
led to new conclusions regarding the mechanism of protein release from these 
networks.  As expected, varying the network hydrophobicity (MCPH:MSA ratio or 
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PEGDA content) altered the release profiles to achieve varying rates of protein release 
from the matrices.  Surprisingly, these effects were seen primarily in the later phases 
(>7 days) of release.  Interestingly, especially during the early phases of protein release, 
the physicochemical properties of individual proteins were a dominant factor in 
determining protein release.   
If the mechanism for protein release were dictated purely by erosion of the 
polymer network, it would be expected that the release profile would be near-zero order 
and unrelated to protein molecular weight.  However, protein molecular weight played a 
dominant role.  The mechanism for protein release in the short-term appeared to be 
diffusion through matrix channels.  As a result, release was dictated by protein 
properties (solubility and diffusivity) as well as by matrix properties (porosity and 
tortuosity).  Small molecular weight macromolecules were incapable of inducing 
substantial matrix porosity, therefore hindering release.  Also contributing to this theory 
that matrix porosity and protein properties were dominant factors in protein release was 
the observation that MCPH:MSA ratio, the main contributor to degradation rate, was not 
a good predictor of amount of protein release during the short-term.  In contrast, after 
roughly 7 days of release, network hydrophobicity began to play the expected role in 
modulating protein release. 
In prior work, alteration of monomers failed to achieve modulation of protein 
release in the short-term, therefore other avenues have been explored.  Since porosity 
played a dominant role in dictating protein release, modifications in network porosity 
have been explored.  Particulate leaching strategies are used in TE to induce porosity in 
scaffolds.  In this process, leachable porogens such as salt or gelatin microparticles are 
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incorporated uniformly into a scaffold.  By incubation in aqueous buffer, the leachables 
are removed, leaving a uniformly porous scaffold.  In the current study, the particulate 
leaching strategy was employed to fine tune protein release from photocrosslinked PA 
networks.  Gelatin microparticles (250 µm) or NaCl particles (<106 µm) were 
incorporated into photocrosslinked PA matrices of identical formulations.  In specimen 
with gelatin microparticles, burst effect, long-term release rate, and total cumulative 
release rate of HRP were increased in comparison with unmodified networks (Fig. 2).  
However, in specimen containing NaCl particles, there was only a significant increase in 
burst release behavior. This suggests that the leaching of dissolved gelatin leaves an 
aqueous path, whereas the complete ionic dissolution of NaCl does not result in new 
aqueous pathways or macroporosity for protein diffusion and release.   
Particulate leaching of gelatin microparticles for facilitation of HRP release from 
photocrosslinked PA networks was further pursued.  Initially, gelatin microparticles of 
two sizes (180-250 µm or 250-300 µm) were incorporated into photocrosslinked PA 
networks at a loading of 75 v/v%.  In this system, microparticle size played no role in the 
burst release or release rate during the first 8 days (Fig 3).  However, after eight days, 
matrices with larger microparticles resulted in a higher rate of protein release.  Since 75 
v/v% was the upper limit for microparticle loading, and did result in some fracture during 
degradation, lower levels of loading were explored. A fractional factorial design of 
formulations was prepared with a high and low MCPH:MSA ratio (70:30 and 30:70), 
microparticle loading (55 v/v% and 33 v/v%) and gelatin microparticle size (180-250 µm 
and 106-180 µm).  Interestingly, protein release was independent of both MCPH:MSA 
ratio and microparticle loading (Fig. 4).  The larger gelatin microparticle size significantly 
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increased cumulative protein release, although this was primarily a result of protein 
release during the initial 48 hours.  These data demonstrate that protein release can be 
modulated by a particulate leaching strategy.  Regardless of gelatin microparticle size or 
loading, burst release and cumulative release were increased in comparison to 
nonporous matrices in previous studies.  Experimental differences between the 75 v/v% 
loading and the lower (55 and 33 v/v %) loadings could be a result of a failure of the 
lower loadings to reach the percolation threshold for the material   This critical threshold 
concentration of porogens would result in an “infinite cluster” of conducting links, or 
pores through which the buffer can infiltrate (11).  In this system, achieving the 
percolation threshold was not generally feasible; as structural integrity was 
compromised by high (75 v/v%) microparticle loading. 
In addition to their usage in particulate leaching, gelatin microparticles have also 
been utilized for controlled delivery of growth factors as a result of ionic complexation 
capabilities (12).  Microparticles were loaded with protein solutions by partial swelling.  
During release, poorly associated protein was released into the release buffer during 
the initial 24 hours as the microparticles reach equilibrium swelling (Fig 5).  FITC-BSA 
demonstrated a high burst release from gelatin microparticles, yet also appeared to 
yield sustained release throughout the 18 day experimental conditions.  HRP 
demonstrated less of a burst response than FITC-BSA; however HRP release after 6 
days was negligible.  HRP release from smaller microparticles (106-180 µm) was 
greater than HRP release from larger microparticles (180-250 µm), presumably an 
effect of a higher surface area to volume ratio in the smaller microparticles. This 
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difference in cumulative release was primarily dictated by HRP release between days 2 
and 6. 
Finally, further experiments examined the dual release of FITC-BSA and HRP 
from photocrosslinked PA network – gelatin microparticle composites.  The goal of this 
dual release strategy was to create a system that could provide sustained release of 
two or more growth factors at different rates or release profiles.  For example, in a 
system for tissue regeneration, a proliferative growth factor could undergo substantial 
release in the short-term, while a release of a differentiative growth factor could 
dominate in the long-term.  In this study, protein-loaded microparticles were 
encapsulated into the photocrosslinked network along with a wet-granulated protein-
cyclodextrin formulation.  One composite formulation contained FITC-BSA-loaded 
gelatin microparticles and HRP in the wet-granulated phase (Fig. 7). The other 
composite formulation contained HRP-loaded gelatin microparticles and FITC-BSA in 
the wet-granulated phase (Fig. 8).  The strategy of encapsulating drug- or protein-
loaded microparticles in a matrix is commonly used to localize delivery to a specific site.  
In this system, the microparticles additionally confer porosity to the matrix to facilitate 
release of the protein in the wet-granulated phase. 
When FITC-BSA was loaded into gelatin microparticles and HRP was present in 
the wet-granulated phase, surprisingly, there was no detectable release of FITC-BSA 
from the composite.  Additionally, HRP release profiles were similar to profiles from a 
nonporous matrix.  Alternatively, when HRP was loaded into gelatin microparticles and 
FITC-BSA was present in the wet-granulated phase, significant release of both HRP 
and FITC-BSA occurred.  Release was greater than from nonporous matrices in 
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previous studies.  It was surprising that no appreciable release of FITC-BSA was 
detected from the composites containing FITC-BSA in the gelatin phase, although FITC-
BSA does release from gelatin microparticles and HRP release from the matrix was 
observed.  The phenomenon is presumably explained by protein molecular weight (MW) 
and hydrodynamic radius (HR).  The protein in the wet-granulated phase was readily 
solubilized when in contact with buffer.  When the higher molecular weight protein 
(FITC-BSA, MW 67 kDa, HR 36Å) was present in the wet-granulated phase, protein 
diffusion created channels through which the smaller protein (HRP, MW 43 kDa, HR 
30Å) could diffuse as well.  However when the larger protein was in the gelatin 
microparticle phase, the channels created by the smaller protein probably are 
insufficient for the larger protein to transport through (Scheme in Fig. 9).     
Photocrosslinked PA network
Gelatin microparticle
HRP
FITC-BSA
Fig. 9: Proposed mechanism for dual protein release from photocrosslinked PA 
network-gelatin microparticle composites.  
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Conclusions 
 This study details a means of modulating delivery of proteins from an injectable 
degradable system by incorporation of gelatin microparticles into the photocrosslinked 
PA system.  Since protein diffusivity and matrix porosity in addition to matrix 
degradation were dominant factors in controlling protein release in previous studies, 
here we have focused on incorporation of porogens for increasing levels of protein 
release.  When gelatin microparticles were included in matrices, microparticle size 
appeared to be the predominant factor affecting HRP release, with microparticle loading 
having no appreciable effect.   Gelatin microparticles were also explored as a delivery 
vehicle.  Both microparticle size and protein type (FITC-BSA or HRP) affected protein 
release from gelatin microparticles.  By loading the protein in the gelatin microparticles, 
additional control over protein release was achieved.  Furthermore, a dual release 
system has been demonstrated by incorporation of protein in both the PA matrix and the 
gelatin microparticles.  Variation of system parameters – microparticle size, loading 
percentage, and protein loading of the microparticles – provide a versatile methodology 
for tailoring release profiles from photocrosslinked PA system.  Future work will include 
further elucidation of the mechanisms of release, including porosity and aqueous 
channel formation. 
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CHAPTER V 
 
CONCLUSIONS AND FUTURE WORK 
 
Summary of Manuscripts 
 This dissertation is composed of three manuscripts which detail the optimization 
of the photocrosslinked polyanhydride (PA) system for tissue engineering and drug 
delivery applications.  Each manuscript corresponds to one of the three specific aims 
detailed in Chapter I.  Together, these three aims describe the development of a 
versatile biomaterial for usage in spinal fusion applications. 
 In Chapter II, the photocrosslinked PA system was enhanced by the inclusion of 
PEGDA and CaCO3 as additives.  The incorporation of additives did not alter the curing 
ability or formability of the system.   Incorporation of PEGDA and CaCO3 served both to 
decrease water uptake and to modulate local acidity during degradation.  The inclusion 
of CaCO3 enabled maintenance of compressive modulus throughout the degradative 
lifetime of the material.  In this study, we have revealed additional mechanisms for 
tuning material properties via incorporation of additive agents to expand the scope and 
functionality of the system. Finally, this study demonstrated that additives can be easily 
and successfully incorporated into photocrosslinked PA networks to address a variety of 
physical characteristics.   
Chapter III detailed the first study to evaluate protein release from 
photocrosslinked PA networks.  The modifications described in Chapter II were used in 
this system.  One important result of this work was that sustained long-term release (> 4 
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months) of macromolecules in their active form from photocrosslinked PA networks was 
feasible.  Three model proteins, that differ in their physicochemical and detection 
modalities have been incorporated into the matrices and released in vitro.   By varying 
the network hydrophobicity (MCPH:MSA ratio or PEGDA content) the release profiles 
were tuned to achieve varying rates of protein release from the matrices.  This 
observation constituted a novel mechanism for controlling macromolecular release from 
hydrophobic matrices. Interestingly, especially during the early phases of protein 
release, the physicochemical properties of individual proteins were a dominant factor in 
determining protein release.  These findings validated the photocrosslinked PA system 
as an injectable vehicle for macromolecule delivery with broad clinical applications.  
Chapter IV is a direct extension of the studies described in Chapter III. The 
release rate of proteins in Chapter III was slower than may be desirable for in vivo 
applications. This study detailed a means of modulating delivery of proteins from an 
injectable degradable system by incorporation of gelatin microparticles into the 
photocrosslinked PA system.  Since protein diffusivity and matrix porosity in addition to 
matrix degradation were dominant factors in controlling protein release in previous 
studies, here we focused on incorporation of porogens for increasing levels of protein 
release.  When gelatin microparticles were included in matrices, microparticle size 
appeared to be the predominant factor affecting HRP release, although microparticle 
loading was also evaluated.   Gelatin microparticles were also explored as a delivery 
vehicle.  Both microparticle size and protein type (FITC-BSA or HRP) affected protein 
release from gelatin microparticles.  When protein-loaded microparticles were 
incorporated into photocrosslinked PA networks, release behavior was greatly 
 124
dependent on the protein.  Variation of these parameters – microparticle size, loading 
percentage, and protein loading of the microparticles – provided a versatile 
methodology for tailoring release profiles from photocrosslinked PA system.  
In summary, the studies this from dissertation have optimized the 
photocrosslinked PA system.  By incorporation of additives, the material properties have 
been modulated to minimize water uptake and acidity during degradation, while 
preserving mechanical strength.  Next, the system was further modified to enable long-
term release of active proteins.  Theories were developed as to mechanisms of protein 
release during different phases.  Finally, based on these theories, protein release from 
the system was enhanced through the incorporation of water soluble porogens.  These 
results demonstrate progress toward the development of an injectable, biodegradable 
material for spinal fusion, with an end goal of releasing osteoinductive factors for 
promotion of new bone growth in spinal fusion applications. 
 
Future Work 
 The photocurable polyanhydride system has numerous advantages for 
applications in spinal fusion.  First, the photocurable nature of the system, by virtue of 
methacrylate groups, allows formation of the network in situ, thereby enabling 
conformability of the material to the desired region.  Second, upon crosslinking, the 
network’s modulus is comparable to that of cortico-cancellous bone, and hence is less 
likely to shield the bone from normal stresses, allowing for bone remodeling.   The ratios 
of monomers can be altered to fit nearly any degradation rate.  Up to 30 wt% of the 
formulation can consist of non-reactive additives (inorganic fillers or porogens, growth 
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factors, or viscosity modifiers) without altering crosslinking kinetics.  Photocuring allows 
a more extensive handling time prior to crosslinking than is typically possible with 
chemical crosslinking. By combining chemical and photo crosslinking, both the handling 
time and depth of cure are increased.  Finally, system biodegradability eliminates the 
need for secondary surgeries to remove the device.   
 Development of this photo-curable poly(anhydride) system into an 
osteoconductive, osteoinductive biomaterial for use in spinal applications will be a 
paradigm shift. There is currently no material that provides immediate structural stability 
and is biodegradable over time.  While minimally invasive procedures such as 
vertebroplasty and kyphoplasty are also envisioned as a long-term application for this 
biomaterial, the initial future studies will focus on spinal fusion.  We feel that by 
evaluating our material in a well-validated animal model for spinal fusion (posterolateral 
intertransverse arthrodesis in the New Zealand white rabbit) we can demonstrate the full 
range of material capabilities and biocompatibility.   
The New Zealand white rabbit model for posterolateral intertransverse (PLIT) 
lumbar arthrodesis has been a well-described, well-accepted and prevalent model for 
spinal fusion since its description by Boden in 1995 (1-3).  Model utility is based on 
several factors, including approximation to human surgical procedure, healing 
environment, and nonunion rate (4).  The surgical anatomy (4) and operative technique 
(5) have been thoroughly described in the literature.  The model has been applied to 
study the effects of diverse parameters on the bone biology of lumbar fusion – including 
bone graft substitutes, growth factors, or gene therapy (6-11).  We have selected this 
model to demonstrate the potential of our PA system to facilitate spinal fusion. 
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Initial animal studies will involve the use of the photocrosslinked PA system as an 
extender to autograft.  Morselized autograft from iliac crest will be mixed with the 
monomer paste, and used in the PLITF model.  Three experimental groups will be 
assessed to accomplish this aim.  In the control group, the fusion material will be 
morselized autograft bone, harvested from iliac crest during surgery.  In experimental 
group 1, the fusion material will be the poly(anhydride) network, which will be 
crosslinked in situ. In experimental group 2, the fusion material will be a mixture of the 
PA network and morselized autograft bone.  Data collected from this study will include: 
histology, histomorphometry, planar x-ray, microCT, and DEXA imaging.  
Biocompatibility, as well as osteogenicity will be evaluated.  Subsequent studies will 
involve the replacement of the autograft + polymer group with a group that receives 
polymer mixed with formulated BMP-2, for osteoinduction.  Success of this material 
(defined as fusion that is comparable to that of autograft) in spinal fusion applications is 
the end goal.  In summary, the research that stems from the work in this dissertation will 
provide a major advance in osteoconductive, osteoinductive biomaterials for use in 
spine applications.   
 
References 
1. Boden, S. D., Schimandle, J. H., and Hutton, W. C. (1995) An experimental 
lumbar intertransverse process spinal fusion model. Radiographic, histologic, and 
biomechanical healing characteristics. Spine 20, 412-420. 
2. Boden, S. D., Schimandle, J. H., Hutton, W. C., and Chen, M. I. (1995) 1995 
Volvo Award in basic sciences. The use of an osteoinductive growth factor for lumbar 
spinal fusion. Part I: Biology of spinal fusion. Spine 20, 2626-2632. 
 
3. Boden, S. D., Schimandle, J. H., and Hutton, W. C. (1995) 1995 Volvo Award in 
basic sciences. The use of an osteoinductive growth factor for lumbar spinal fusion. Part 
II: Study of dose, carrier, and species. Spine 20, 2633-2644. 
 127
 
4. Palumbo, M., Valdes, M., Robertson, A., Sheikh, S., and Lucas, P. (2004) 
Posterolateral intertransverse lumbar arthrodesis in the New Zealand White rabbit 
model: I. Surgical anatomy. Spine J 4, 287-292. 
 
5. Valdes, M., Palumbo, M., Appel, A. J., McAllister, S., and Ehrlich, M. (2004) 
Posterolateral intertransverse lumbar arthrodesis in the New Zealand White rabbit 
model: II. Operative technique. Spine J 4, 293-299. 
 
6. Lindfors, N. C., Tallroth, K., and Aho, A. J. (2002) Bioactive glass as bone-graft 
substitute for posterior spinal fusion in rabbit. J Biomed Mater Res 63, 237-244. 
 
7. Namikawa, T., Terai, H., Suzuki, E., Hoshino, M., Toyoda, H., Nakamura, H., 
Miyamoto, S., Takahashi, N., Ninomiya, T., and Takaoka, K. (2005) Experimental spinal 
fusion with recombinant human bone morphogenetic protein-2 delivered by a synthetic 
polymer and beta-tricalcium phosphate in a rabbit model. Spine 30, 1717-1722. 
 
8. Minamide, A., Kawakami, M., Hashizume, H., Sakata, R., Yoshida, M., and 
Tamaki, T. (2004) Experimental study of carriers of bone morphogenetic protein used 
for spinal fusion. J Orthop Sci 9, 142-151. 
 
9. Hile, D. D., Kandziora, F., Lewandrowski, K. U., Doherty, S. A., Kowaleski, M. P., 
and Trantolo, D. J. (2005) A poly(propylene glycol-co-fumaric acid) based bone graft 
extender for lumbar spinal fusion: in vivo assessment in a rabbit model. Eur Spine J. 
  
10. Alden, T. D., Pittman, D. D., Beres, E. J., Hankins, G. R., Kallmes, D. F., 
Wisotsky, B. M., Kerns, K. M., and Helm, G. A. (1999) Percutaneous spinal fusion using 
bone morphogenetic protein-2 gene therapy. J Neurosurg 90, 109-114. 
 
11. Mooney, V., Massie, J. B., Lind, B. I., Rah, J. H., Negri, S., and Holmes, R. E. 
(1998) Comparison of hydroxyapatite granules to autogenous bone graft in fusion cages 
in a goat model. Surg Neurol 49, 628-633; discussion 633-624. 
 
 128
APPENDIX A 
 
 
 
RATIONALE FOR SELECTION OF POLYMER FORMULATIONS FOR SPECIFIC 
AIMS TWO AND THREE 
 
 
 
 Based on our preliminary results, we have selected a formulation of monomers, 
inorganic fillers and photoinitiators that have yielded the most desirable properties in 
vitro.  First, the anhydride portion of the formulation will be composed of MCPH and 
MSA in a ratio of 70:30.  The balance of this parameter is responsible for the rate of 
mass loss, the pH profile on degradation, as well as the mechanical strength.  Next, the 
overall composition should be 10 wt% PEGDA (MW 700).  This amount is sufficient to 
provide viscosity modification and to improved depth of cure and crosslinking resultant 
from the highly reactive diacrylate functionality.  The improvement in crosslinking 
diminishes swelling during network degradation.  The inorganic filler calcium carbonate 
(CaCO3) should be present at 10 wt%, to serve as a moderate porogen and as a 
significant pH buffer during the course of degradation.  Finally, the photoinitiators should 
be included at 0.1 wt%.  This photoinitiator concentration provides excellent depth of 
cure within 10 minutes in our human cadaver corpectomy model, while allowing a 
reasonable working time after adding initiators.  In addition, we have demonstrated that 
photocrosslinking can occur with an additional 10 wt% of nonreactive fillers, allowing the 
supplementation of this formulation with proteins without affecting the polymerization 
efficacy. This level of in vitro testing will provide our collaborators and others in the field 
with an unprecedented level of insight, thereby enabling tests of function in a direct and 
highly efficient manner.  Table 1 summarizes the network components. 
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Table 1: Rationale for polymer formulation 
Parameter Composition Rationale 
Anhydride ratio (MCPH:MSA) 70:30  Mass loss 
pH 
Mechanical 
properties 
PEGDA 10 wt% Viscosity modification 
Depth of cure 
Calcium carbonate 10 wt% pH buffer 
Porogen 
Benzoyl Peroxide 
Dimethyl Toluidine 
Camphorquinone 
Ethyl 4-dimethylaminobenzoate 
0.1 wt% 
0.1 wt% 
0.1 wt% 
0.1 wt% 
Chemical crosslinking 
 
Photo-crosslinking 
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APPENDIX B 
 
 
 
INCORPORATION OF BARIUM SULFATE INTO PHOTOCROSSLINKED 
POLY(ANHYDRIDE) NETWORKS 
 
 
 
Radio-opacity must be conferred to the polymer if it is to be visualized after 
implantation.  This allows the clinical outcome to be easily followed via x-ray.  In a proof-
of-concept experiment, barium sulfate (BaSO4) was mixed into a mixture of 
methacrylated anhydride monomers and photocrosslinked.  The specimen were 
embedded in agarose phantoms and imaged by planar x-ray.  In Fig. 1, two samples 
containing BaSO4 (top and bottom right) show more contrast than a photocrosslinked 
poly(anhydride) network without BaSO4 (bottom left). BaSO4 incorporation within the 
network clearly improves contrast on x-ray without affecting curing parameters. 
 
 
 
Fig. 1: Photocrosslinked poly(anhydride) 
networks without BaSO4 (bottom left) or 
with BaSO4 (top and bottow right).  
BaSO4 incorporation within the network 
clearly improves contrast on x-ray 
without affecting curing parameters. 
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APPENDIX C 
 
 
INCORPORATION OF MORSELIZED BONE INTO PHOTOCROSSLINKED 
POLY(ANHYDRIDE) NETWORKS 
 
 
 
Producing crosslinked poly(anhydride) matrices containing autogenous bone 
from the iliac crest is a vital component of future work. To evaluate feasibility of an 
experimental group containing a mixture of autograft and polymer, two formulations 
were crosslinked.  The first contained 50% iliac crest autograft and 50% polymer 
formulation (by mass), and the second contained 35% iliac crest autograft and 75% 
polymer formulation.  Both formulations crosslinked into uniform discs (5 mm height, 10 
mm diameter), although after a curing time of 10 minutes, the 50:50 sample required 
showed evidence of inhomogeneous curing. The 25:75 samples polymerized in less 
than 5 minutes.  Samples containing morselized bone (Fig. 1 a 25:75, b 50:50) were 
imaged by scanning electron microscopy (SEM, Hitachi S-4200) to demonstrate more 
porous network architecture than unmodified polymer formulations.  As a result of the 
lengthened crosslinking time and inhomogeneous curing for the 50:50 formulation, the 
25:75 formulation has been selected for future studies. 
 
  
Fig. 1: SEM images of photocrosslinked 
poly(anhydrides) containing A) 25% morselized bone 
and B) 50% morselized bone. 
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APPENDIX D 
 
 
 
IN SITU PHOTOCROSSLINKING IN HUMAN CADAVER SPINE 
 
 
 
To evaluate proof of principle for photocrosslinking the poly(anhydride) system in 
the spine, a modified corpectomy model was assessed in a human cadaver spine (Fig. 
1).  A partial corpectomy was performed on a thoracic vertebral body.  The polymer 
formulation was mixed and poured into the excised region.  The polymer network was 
formed via curing with a blue dental lamp (CuringLight XL1500) for 10 minutes.  The 
crosslinked network was removed from the defect.  The polymer network meshed with 
existing bone and perfectly filled the defect, verifying feasibility of this strategy in vivo.  
The crosslinked polymer in this scenario was 3 cm in width and 1.5 cm in height, 
demonstrating that complete curing can occur in a reasonable timeframe even on larger 
samples. 
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Fig. 1: A. Thoracic region of a human cadaver spine.  B. Partial 
corpectomy of a thoracic vertebral body.  C. Mixture of anhydride 
monomers was poured into the corpectomy region. D.  
Photocrosslinking the PA network in the corpectomy region of a 
human cadaver spine.  E.  Photocrosslinked PA network removed 
from the corpectomy region.  F.  Alternative view of the back of 
the photocrosslinked PA network, demonstrating a complete 
filling of the void space.  G. Cross-section of the photocrosslinked 
PA) network, demonstrating crosslinking throughout the depth of 
the material. 
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APPENDIX E 
 
PHOTOCROSSLINKED POLY(ANHDRIDES) IN A RABBIT MODEL FOR 
POSTEROLATERAL INTERTRANSVERSE FUSION 
 
 
 
Surgical procedure 
 Posterolateral intertransverse arthrodesis was performed as described by 
Valdes et al (1).  The dorsal aspect of the lumbar spine was shaved.  The skin was 
prepared using sterile technique, and the spinal level to be fused, L5-L6, was identified 
by palpation.  A dorsal midline incision of approximately 6 cm in length was made over 
the L5-L6 level. The skin and subcutaneous tissue was retracted.  A 4-6 cm incision 
through the lumbar fascia was made, approximately 2 cm lateral to the midline. The 
iliocostalis muscle was divided to reveal the longissimus muscle, which underwent blunt 
dissection at the lateral border to reveal the transverse processes.  The graft material 
was placed over the intertransverse ligament, spanning the distance between the L5 
and L6 transverse processes.   Fig. 1A shows the crosslinked matrices during the 
surgical procedure. Harvest of iliac crest autograft was carried out concurrently with the 
posterolateral intertransverse spinal fusion procedure, as described by Valdes et al (1). 
The middle two thirds of the iliac crest was exposed (greatest amount of cancellous 
bone at this location).  For this study, the harvest of only one iliac crest was required.  
The graft on the right side of the animal consisted of polymer alone, supplemented with 
10 mg BaSO4 to provide radio-opacity.  The graft on the left side of the spine was 
composed of polymer + 25% iliac crest autograft.   Photocrosslinking of the polymer 
graft required 3 minutes of exposure to a blue dental lamp for the BaSO4 modified side 
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and 6 minutes of exposure for the polymer+autograft side.  A 3-0 vicryl suture was used 
for muscle and lumbodorsal fascia.  2-0 nylon sutures were used along the incision.  
 Following this, the lumbar spine was explanted for analysis using microCT. The 
planar x-ray and DEXAscan were carried out with the assistance of Dr. Ed Donnelly at 
the Vanderbilt Institute of Imaging Sciences (VUIIS) Small Animal Imaging Facility.  The 
microCT was carried out with the assistance of Dr. Todd Peterson at the VUIIS Small 
Animal Imaging Facility. 
 
Planar x-ray 
 Radiographs were taken in the anteroposterior plane using a Faxitron 
Radiography X-ray (Wheeling, IL).  Radiographs were taken at 60 kV with a 10 s 
exposure and a digital acquisition system.  Both the specimen containing BaSO4 and 
the specimen containing morselized autograft had sufficient contrast to be visualized on 
the x-ray image (Fig. 1B). 
 
microCT 
 The Imtek MicroCAT II scanner is an X-ray computed tomography system 
capable of performing imaging studies of small animals in vivo or specimens. The 
microCT images were reconstructed and analyzed using Amide software.  The 3D 
reconstruction can be seen in Fig. 1C.  In Fig. 1D and 1E, slices of the coronal plane 
and transverse plane can be seen respectively. In both Fig.s 1D and E, the specimen 
containing autograft is seen on the left, and the specimen with BaSO4 can be seen on 
the right. Both the polymer specimen containing BaSO4 and morselized autograft were 
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clearly visible on the microCT reconstructions.  The specimen containing BaSO4 
showed more contrast than the specimen containing morselized autograft.  However, 
the pieces of morselized bone in the polymer + autograft specimen were clearly evident 
in most CT slices.  This finding validates our strategy for using microCT as a metric for 
determining fusion in our studies as we will be able to detect bone within the polymer. 
 
Dual energy x-ray absorptiometry (DEXA) 
 A GE Lunar PIXImus bone densitometer was used to evaluate the bone density 
in the regions of polymer and polymer + autograft.  The image obtained from the 
densitometer is seen in Fig. 1F. From this image, six fields of 10 by 11 pixels were 
evaluated for bone density (g/cm2).  The specimen containing bone autograft had a 
significantly greater bone density than the BaSO4 specimen (p<0.05). This data is 
shown in Fig. 1G. This result suggests that bone within the polymer can be both 
detected and quantified within the polymer specimen. 
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Fig. 1:  A. Surgical procedure of the rabbit 
posterolateral intertransverse fusion after 
implantation and photocrosslinking. B.  
Planar x-ray.  C. microCT reconstruction.  D. 
microCT coronal view.  E. microCT 
transverse view.  F. DEXA image, coronal 
view.  G. Average bone mineral density for 
the polymer + BaSO4 specimen and the 
polymer + autograft specimen as calculated 
by DEXA. 
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